Evaxion Biotech A/S(EVAX)

1.31+0.01+1.09%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Evaxion to present at World Vaccine Congress
  GlobeNewswire · 04-10
  Evaxion to present at World Vaccine Congress
- European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading
  MT Newswires Live · 04-07
  European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading
- Evaxion Biotech’s Optimistic Earnings Call Highlights
  TIPRANKS · 04-03
  Evaxion Biotech’s Optimistic Earnings Call Highlights
- Evaxion Biotech Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
  Dow Jones · 04-02
  Evaxion Biotech Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
- Evaxion Biotech AS (EVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and ...
  GuruFocus.com · 04-02
  Evaxion Biotech AS (EVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and ...
- Q4 2024 Evaxion Biotech A/S Earnings Call
  Thomson Reuters StreetEvents · 04-02
  Q4 2024 Evaxion Biotech A/S Earnings Call
- European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading
  MT Newswires Live · 04-01
  European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading
- Evaxion Biotech A/S reports results for the quarter ended December 31 - Earnings Summary
  Reuters · 04-01
  Evaxion Biotech A/S reports results for the quarter ended December 31 - Earnings Summary
- Evaxion Biotech Q4 EPS $(0.07) Beats $(0.15) Estimate, Sales $122.00K Miss $1.66M Estimate
  Benzinga · 04-01
  Evaxion Biotech Q4 EPS $(0.07) Beats $(0.15) Estimate, Sales $122.00K Miss $1.66M Estimate
- Evaxion Announces Business Update and Full Year 2024 Financial Results
  THOMSON REUTERS · 04-01
  Evaxion Announces Business Update and Full Year 2024 Financial Results
- Evaxion announces business update and full year 2024 financial results
  GlobeNewswire · 04-01
  Evaxion announces business update and full year 2024 financial results
- Evaxion Biotech A/S expected to post a loss of $3.88 a share - Earnings Preview
  Reuters · 03-28
  Evaxion Biotech A/S expected to post a loss of $3.88 a share - Earnings Preview
- Evaxion to announce business update and full year 2024 financial results on April 1, 2025
  GlobeNewswire · 03-27
  Evaxion to announce business update and full year 2024 financial results on April 1, 2025
- European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
  MT Newswires Live · 03-25
  European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
- Evaxion Biotech A/S expected to post a loss of $3.88 a share - Earnings Preview
  Reuters · 03-21
  Evaxion Biotech A/S expected to post a loss of $3.88 a share - Earnings Preview
- European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
  MT Newswires Live · 03-20
  European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
- Evaxion Biotech a/S Files for Stock Shelf of up to $50 Mln- SEC Filing
  THOMSON REUTERS · 03-13
  Evaxion Biotech a/S Files for Stock Shelf of up to $50 Mln- SEC Filing
- European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading
  MT Newswires Live · 03-13
  European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading
- European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading
  MT Newswires Live · 03-10
  European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading
- European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading
  MT Newswires Live · 03-05
  European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading
Company Profile
Company Name
Evaxion Biotech A/S
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.evaxionbiotech.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
- 04-01
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 01-28
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 01-28
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-12-17
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-12-05
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-11-18
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-11-14
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-06
  Beneficial Ownership Change
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 2024-08-20
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-08-20
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-07-22
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-07-22
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-05-06
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-03-26
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-01-31
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

1D
5D
Day
Week
Month

Loading ...

High

1.32

Open

1.31

Volume%

1.13

Low

1.28

1.30

T/O Rate

0.32%

{"pagemeta":{"title":"Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Evaxion Biotech A/S(EVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Evaxion Biotech A/S,EVAX,Evaxion Biotech A/S股票,Evaxion Biotech A/S股票老虎,Evaxion Biotech A/S股票老虎国际,Evaxion Biotech A/S行情,Evaxion Biotech A/S股票行情,Evaxion Biotech A/S股价,Evaxion Biotech A/S股市,Evaxion Biotech A/S股票价格,Evaxion Biotech A/S股票交易,Evaxion Biotech A/S股票购买,Evaxion Biotech A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Evaxion Biotech A/S(EVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}},"tab":"news","symbol":"EVAX","data":{"stockData":{"symbol":"EVAX","market":"US","secType":"STK","nameCN":"Evaxion Biotech A/S","latestPrice":1.3142,"timestamp":1745335275755,"preClose":1.3,"halted":0,"volume":15081,"delay":0,"floatShares":4709862,"shares":6266572,"eps":-9.849099,"marketStatus":"Trading","change":0.0142,"latestTime":"04-22 11:30:53 EDT","open":1.31,"high":1.32,"low":1.28,"amount":19636.422659699998,"amplitude":0.030769,"askPrice":1.32,"askSize":53,"bidPrice":1.31,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.849099,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745352000000},"marketStatusCode":2,"adr":0,"adrRate":50,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":1.3,"preHourTrading":{"tag":"盘前","latestPrice":1.35,"preClose":1.3,"latestTime":"09:21 EDT","volume":1535,"amount":2068.8924945,"timestamp":1745328072453},"postHourTrading":{"tag":"盘后","latestPrice":1.2904,"preClose":1.305,"latestTime":"17:09 EDT","volume":561,"amount":725.924,"timestamp":1745269747131},"volumeRatio":1.129357,"impliedVol":2.1042,"impliedVolPercentile":0},"tweetData":null,"newsData":{"listData":[{"id":"2526563412","title":"Evaxion to present at World Vaccine Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2526563412","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526563412?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:00","pubTimestamp":1744286400,"startTime":"0","endTime":"0","summary":"Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/10/3059207/0/en/Evaxion-to-present-at-World-Vaccine-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"gpt_icon":0},{"id":"2525028963","title":"European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2525028963","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525028963?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 23:09","pubTimestamp":1744038542,"startTime":"0","endTime":"0","summary":"Continuing their decline from last week, European equities traded in the US as American depositary receipts were sharply lower late Monday morning, falling 1.73% to 1,257.11 on the S&P Europe Select A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVO.AU","EVAX","NTZ","LU0109394709.USD","BK7507","DAVA.AU","TRIB","LU0124676726.USD","LU0689626769.HKD","BK4107","BK4139","BK4201","BHP.AU","LU0648005311.SGD","BK4183","BK4588","E","LU1093756168.USD","GSK.UK","BK4568","AKTX","LU2417539215.USD","UL","DAVA","IE00BKVL7J92.USD","BDRX","LU1093756325.SGD","SLN","GSK","UN","BK7104","GRFS","BK4599","BK4007","BK4117","BK4095","ASND","IE00BZ1G4Q59.USD","LU0084288595.USD","AFG","BK4532","LU0889565916.HKD","ULVR.UK","LU2456880835.USD","AZN","BHP","DBVT","LU0154236417.USD","BK7095"],"gpt_icon":1},{"id":"2524429398","title":"Evaxion Biotech’s Optimistic Earnings Call Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2524429398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524429398?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 08:05","pubTimestamp":1743638742,"startTime":"0","endTime":"0","summary":"Evaxion Biotech A/S Adr (($EVAX)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for Evaxion ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evaxion-biotechs-optimistic-earnings-call-highlights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evaxion-biotechs-optimistic-earnings-call-highlights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2524142469","title":"Evaxion Biotech Price Target Maintained With a $14.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524142469","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524142469?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 19:15","pubTimestamp":1743592500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 07:15 ET (11:15 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX"],"gpt_icon":0},{"id":"2524143788","title":"Evaxion Biotech AS (EVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524143788","media":"GuruFocus.com","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524143788?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 15:00","pubTimestamp":1743577229,"startTime":"0","endTime":"0","summary":"Revenue: $3.3 million from the option and license agreement with MSD.Cash and Cash Equivalents: $6 million as of December 2024, up from $5.6 million at the end of 2023.Net Loss: $10.6 million for 2024, equating to $0.20 per basic and diluted share.Operational Cash Burn: Expected to be $14 million for 2025, consistent with 2024.Cash Runway: Sufficient funds to cover operating and capital expenditures into mid-2026.Equity Improvement: Cash and cash equivalents of $11.9 million as of January 27, 2025, with an additional $10.8 million from a public offering closing on January 31, 2025.GuruFocus has detected 3 Warning Signs with EVAX.Evaxion Biotech AS  has extended its cash runway to mid-2026 through public offerings and investments from MSD Global Health Innovation Fund.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/evaxion-biotech-evax-q4-2024-070029794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evaxion Biotech AS (EVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and ...","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EVAX"],"gpt_icon":0},{"id":"2524102094","title":"Q4 2024 Evaxion Biotech A/S Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2524102094","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524102094?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 11:18","pubTimestamp":1743563880,"startTime":"0","endTime":"0","summary":"Christian Kanstrup; Chief Executive Officer; Evaxion Biotech A/S. Swayampakula Ramakanth; Analyst; H.C. Wainwright & Co., LLC. Good day, and thank you for standing by. Welcome to the Evaxion Biotech business update full year 2024 conference call and webcast.  Please note that today's conference is being recorded.I would now like to hand the conference over to your speaker, Christian Kanstrup, CEO. Please go ahead.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-evaxion-biotech-earnings-031800853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EVAX"],"gpt_icon":0},{"id":"2524014307","title":"European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2524014307","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524014307?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:11","pubTimestamp":1743520287,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were treading water late Tuesday morning, edging 0.02% higher to 1,397.86 on the S&P Europe Select ADR Index.From continental Europe,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NOK","BK4201","BK4020","WPP.AU","BK4207","GNFT","LU0889565916.HKD","BK4547","NCNA","BK7142","AFG","IE00BMPRXR70.SGD","EVAX","BK4521","BK4139","SAN.AU","TRIB","AUTL","BK4585","LU0109394709.USD","BK4007","IE00BMPRXN33.USD","BK4588","DBVT","BCYC","BK4082","EDAP","BK4009","AKTX","BK4107","SLN","EQNR","WPP","BK4117","ADAP","SAN","LU0320765992.SGD","ASND"],"gpt_icon":0},{"id":"2524211464","title":"Evaxion Biotech A/S reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524211464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524211464?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 21:32","pubTimestamp":1743514346,"startTime":"0","endTime":"0","summary":"Evaxion Biotech A/S reports results for the quarter ended December 31 - Earnings SummaryEvaxion Biotech A/S EVAX.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended Decemb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nL5N3QF10Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK","EVAX"],"gpt_icon":0},{"id":"2524197098","title":"Evaxion Biotech Q4 EPS $(0.07) Beats $(0.15) Estimate, Sales $122.00K Miss $1.66M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197098","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197098?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:46","pubTimestamp":1743507965,"startTime":"0","endTime":"0","summary":"Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 99.56 percent increase over losses of $(16.00) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44582662/evaxion-biotech-q4-eps-0-07-beats-0-15-estimate-sales-122-00k-miss-1-66m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX"],"gpt_icon":0},{"id":"2524197820","title":"Evaxion Announces Business Update and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197820?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:30","pubTimestamp":1743507035,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUA2FDDZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2524611541","title":"Evaxion announces business update and full year 2024 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524611541","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524611541?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:30","pubTimestamp":1743507000,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S  , a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and announces full year 2024 financial results.Business highlights2024 and the first months of 2025 saw Evaxion make substantial progress in both business development, research and development and financing. Key highlights are listed below.“Evaxion has made significant progress over the past 15 months and the company has never been stronger fundamentally. We maintain our strong momentum in strategy execution and have already achieved our first 2025 company milestone with the completion of dosing in the EVX-01 phase 2 trial in January. Having demonstrated our ability to derive value from both our AI-Immunology platform and our pipeline, we continue our efforts to create long-term value based on our multi-partner strategy. We are confident in our ability to deliver on our 2025 milestones focusing on business devel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/evaxion-announces-business-full-2024-113000099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EVAX","BK4139"],"gpt_icon":0},{"id":"2522716815","title":"Evaxion Biotech A/S  expected to post a loss of $3.88 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522716815","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522716815?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:55","pubTimestamp":1743166505,"startTime":"0","endTime":"0","summary":"Evaxion Biotech A/S  expected to post a loss of $3.88 a share - Earnings Preview Evaxion Biotech A/S EVAX.OQ EVAX.O is expected to show a rise in quarterly revenue when it reports  results on April 1 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK"],"gpt_icon":0},{"id":"2522370862","title":"Evaxion to announce business update and full year 2024 financial results on April 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522370862","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522370862?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S  , a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.About EVAXION Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/evaxion-announce-business-full-2024-120000193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2522006169","title":"European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006169","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006169?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:08","pubTimestamp":1742915311,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were higher late Tuesday morning, up 0.73% to 1,435.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were l","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4134","BDRX","LU0300736492.USD","LU2129689605.HKD","BNTX","BK7141","BK4585","BK4201","LU2129689514.USD","LU2237443978.SGD","DAVA","LU2237443382.USD","LU0084288595.USD","EDAP","TTE","DAVA.AU","LU0889565916.HKD","AFG","BK4139","ING","LU1162221912.USD","LU0648005311.SGD","ADAP","BK4007","BK7505","BK4505","LU0300736062.USD","MREO","BK4207","ING.AU","NCNA","BK4107","BK4535","LU0098860793.USD","AKTX","SHEL","LU2237443895.HKD","BK4551","LU0320765992.SGD","BK4117","LU2129689431.USD","NTZ","BK4548","LU2237443549.SGD","DBVT","LU2237443465.HKD","SLN","EVAX","LU2236285917.USD","ASND"],"gpt_icon":0},{"id":"2521850812","title":"Evaxion Biotech A/S  expected to post a loss of $3.88 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521850812","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521850812?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:39","pubTimestamp":1742560745,"startTime":"0","endTime":"0","summary":"Evaxion Biotech A/S  expected to post a loss of $3.88 a share - Earnings Preview Evaxion Biotech A/S EVAX.OQ EVAX.O is expected to show a rise in quarterly revenue when it reports  results on March 25","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q412E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK","EVAX"],"gpt_icon":0},{"id":"2520463019","title":"European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2520463019","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520463019?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:13","pubTimestamp":1742483595,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.47% to 1,438.05 on the S&P Europe Select ADR Index.From continental Europe, th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HSBC","TCBPY","00005","BDRX","HSBA.UK","LU0348735423.USD","BBVA","EVAX","BK4117","BK4204","AFG","LU0310800965.SGD","LU0540923850.HKD","LU0149721374.USD","BK7104","ADAP","BK4599","BK4554","AKTX","NVO.AU","SAN.AU","LU1481107354.HKD","BK1572","BK4009","BK4521","CLLS","BK4585","LU1093756168.USD","PSO","CRTO","LU2236285917.USD","HSHD.SI","LU0128525689.USD","TRIB","TRVG","03143","IE00BZ1G4Q59.USD","LU0516423174.USD","BK1610","BK1601","SAN","BK4007","BK4107","BK4588","ERIC","IE00BFMHRM44.USD","TCBP","BK4591","BK4207","NCNA"],"gpt_icon":1},{"id":"2519866728","title":"Evaxion Biotech a/S Files for Stock Shelf of up to $50 Mln- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2519866728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519866728?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 04:03","pubTimestamp":1741896200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW1MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2519855800","title":"European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2519855800","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519855800?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:09","pubTimestamp":1741878554,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were treading water late Thursday morning, edging 0.1% higher to 1,396.7 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS  and pharmaceutical company Novo Nordisk , which rose 4.7% and 3.3% respectively. They were followed by pharmaceutical company Ascendis Pharma  and telecommunications operator Telefonica , which were up 1.7% and 1.5% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications  and software firm SAP , which fell 2.7% and 2.3% respectively. They were followed by biotechnology companies argenx  and Evaxion Biotech , which dropped 2.1% and 0.9% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics  and telecommunications operator Vodafone Group , which increased 5.2% and 3% respectively. They were followed by pharmaceutical companies Amari","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCS","LU2417539215.USD","LU1093756168.USD","BK4207","EVAX","TCBP","IE00BZ1G4Q59.USD","LU2236285917.USD","SQNS","NVO","LU0154236417.USD","BK4115","AKTX","NCNA","LU0109394709.USD","BK4023","BK4613","BK4588","NVO.AU","BK4007","BK4107","BK4141","SAP","LU0320765992.SGD","BK4585","ARGX","AFG","LU2456880835.USD","BK4521","LU2462157665.USD","VOD","BK4599","LU0889565916.HKD","BK4139","AZN","BK4532","LU1829250122.USD","BK7104","SLN","EDAP","BK4117","BK4505","IE00BKVL7J92.USD","ASND","BK4132","BK4568","BK4528","LU1093756325.SGD","AMRN","TEF"],"gpt_icon":1},{"id":"2518027902","title":"European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2518027902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518027902?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 23:20","pubTimestamp":1741620049,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were falling late Monday morning, dropping 2.31% on the S&P Europe Select ADR Index to 1,411.83.From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies  and petroleum refiner Equinor , which rose 6.4% and 5.1%, respectively. They were followed by medical device maker EDAP TMS  and consumer goods giant Unilever , which were up 4.8% and 3.1%, respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk  and financial services company Banco Santander , which fell 10% and 5.7%, respectively. They were followed by biotech firm Evaxion Biotech  and internet browser company Opera , which were down 5.3% each.From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals  and utilities company National Grid , which advanced 11% and 2.8%, respectively. They were followed by biopharmaceutical company TC Biopharm  and oil a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4208","UL","EQNR","BK7104","BK4532","AKTX","NGG","BK4201","BP","UN","BK4082","VRNA","LU1093756325.SGD","LU1162221912.USD","BK4107","DBVT","IE00BZ1G4Q59.USD","NVO","CUK","SAN","BK4023","BK4585","EDAP","ULVR.UK","NVO.AU","BK4183","LU0689626769.HKD","LU0124676726.USD","LU1093756168.USD","IE00BKVL7J92.USD","BK4207","BK4592","BK7142","AFG","TCBP","LU0072461881.USD","OPRA","BK4007","BK4521","BK4599","EVAX","BK4142","LU0154236417.USD","BCS","LU0162691827.USD","LU0320765646.SGD","SAN.AU","BK4117","BDRX"],"gpt_icon":1},{"id":"2517949344","title":"European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2517949344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517949344?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 00:02","pubTimestamp":1741190536,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending sharply higher late Wednesday morning, rising 1.72% to 1,443.47 on the S&P Europe Select ADR Index.From continental Eur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4142","BBVA","EVAX","BK4117","BK4204","AUTL","BK4201","BK4208","AFG","BK4077","ADAP","PUK","BK4532","NGG","DEO","DGE.UK","BK7505","BK4585","BK4095","ING","GRFS","PSO","EQNR","TRVG","BK4139","NTZ","BK4111","BK4107","BK4588","TCBP","BK4162","BK7141","ING.AU","BK4207","GNFT","IHG","BK4169"],"gpt_icon":0}],"currentPage":1,"bottom":false},"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"19332996","market":"us","labels":[],"media":"sec.gov","original_id":"AN117184325001916-EVAX","pdf_url":"","pub_time":1743480000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","symbol":"EVAX","title":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","titleType":"Annual Report","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/0001171843-25-001916-index.htm","us_notice_code":"Form 20-F","us_title_en":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"FORM 20-F","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/evax20241231_20f.htm","primary":true,"translateUrl":"","linkName":"evax20241231_20f.htm","type":"20-F","id":"NTFILE1gj6EeB2CrAVYdiY","market":"us","size":5401475},{"description":"EXHIBIT 11.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/ex_797219.htm","primary":false,"translateUrl":"","linkName":"ex_797219.htm","type":"EX-11.1","id":"NTFILEExtkxmQPCExssq8v","market":"us","size":72755},{"description":"EXHIBIT 12.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/ex_797220.htm","primary":false,"translateUrl":"","linkName":"ex_797220.htm","type":"EX-12.1","id":"NTFILEER5p3Y5WweXwKBWi","market":"us","size":8487},{"description":"EXHIBIT 12.2","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/ex_797221.htm","primary":false,"translateUrl":"","linkName":"ex_797221.htm","type":"EX-12.2","id":"NTFILE8gvAVuXkMQsWHRRS","market":"us","size":8204},{"description":"EXHIBIT 13.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/ex_797222.htm","primary":false,"translateUrl":"","linkName":"ex_797222.htm","type":"EX-13.1","id":"NTFILE93F48uLMuGedBt9G","market":"us","size":3726},{"description":"EXHIBIT 13.2","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/ex_797223.htm","primary":false,"translateUrl":"","linkName":"ex_797223.htm","type":"EX-13.2","id":"NTFILE29Z4GbCTajpA7tfn","market":"us","size":3771},{"description":"EXHIBIT 15.1","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/ex_797224.htm","primary":false,"translateUrl":"","linkName":"ex_797224.htm","type":"EX-15.1","id":"NTFILE4259UnPqdT6XEUuX","market":"us","size":7429},{"description":"EXHIBIT 97.1","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/ex_797225.htm","primary":false,"translateUrl":"","linkName":"ex_797225.htm","type":"EX-97.1","id":"NTFILE5dzgiSUjxxHXeSaU","market":"us","size":27070},{"description":"","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/evaxionlogo.jpg","primary":false,"translateUrl":"","linkName":"evaxionlogo.jpg","type":"GRAPHIC","id":"NTFILEFNJTBwSafoU57mcT","market":"us","size":6533},{"description":"","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig2.jpg","primary":false,"translateUrl":"","linkName":"fig2.jpg","type":"GRAPHIC","id":"NTFILEHMKc14Kzg6rqgdKa","market":"us","size":63938},{"description":"","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig4a.jpg","primary":false,"translateUrl":"","linkName":"fig4a.jpg","type":"GRAPHIC","id":"NTFILE6LPpw5HrJgQCNvBQ","market":"us","size":85113},{"description":"","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig4b.jpg","primary":false,"translateUrl":"","linkName":"fig4b.jpg","type":"GRAPHIC","id":"NTFILEGXYaU5CPa1Hw6BRt","market":"us","size":79137},{"description":"","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig5.jpg","primary":false,"translateUrl":"","linkName":"fig5.jpg","type":"GRAPHIC","id":"NTFILECDuqSBaHzojJHu4X","market":"us","size":44135},{"description":"","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig6.jpg","primary":false,"translateUrl":"","linkName":"fig6.jpg","type":"GRAPHIC","id":"NTFILEAHbfa9XVBndBK9eM","market":"us","size":24131},{"description":"","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig7.jpg","primary":false,"translateUrl":"","linkName":"fig7.jpg","type":"GRAPHIC","id":"NTFILEGQyAUXeRBSC6Eesj","market":"us","size":35660},{"description":"","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig8.jpg","primary":false,"translateUrl":"","linkName":"fig8.jpg","type":"GRAPHIC","id":"NTFILEA2MYYGwebotLSgmF","market":"us","size":45212},{"description":"","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig9.jpg","primary":false,"translateUrl":"","linkName":"fig9.jpg","type":"GRAPHIC","id":"NTFILEEmTUowLEzisdJmCW","market":"us","size":43754},{"description":"","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig10.jpg","primary":false,"translateUrl":"","linkName":"fig10.jpg","type":"GRAPHIC","id":"NTFILEGzoRs613yCSFkEF3","market":"us","size":91348},{"description":"","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig11.jpg","primary":false,"translateUrl":"","linkName":"fig11.jpg","type":"GRAPHIC","id":"NTFILEChaGoKn6UKrKyMm2","market":"us","size":89953},{"description":"","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig12.jpg","primary":false,"translateUrl":"","linkName":"fig12.jpg","type":"GRAPHIC","id":"NTFILEBcyVD9RZKZRoQnpj","market":"us","size":22282},{"description":"","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig13.jpg","primary":false,"translateUrl":"","linkName":"fig13.jpg","type":"GRAPHIC","id":"NTFILE71SUMSfkdHaGCU4y","market":"us","size":28057},{"description":"","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig13b.jpg","primary":false,"translateUrl":"","linkName":"fig13b.jpg","type":"GRAPHIC","id":"NTFILE8gY8ofmK8K7KeU3T","market":"us","size":16521},{"description":"","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig14.jpg","primary":false,"translateUrl":"","linkName":"fig14.jpg","type":"GRAPHIC","id":"NTFILE9Pbn8RJUt6zhGvvC","market":"us","size":36026},{"description":"","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig15.jpg","primary":false,"translateUrl":"","linkName":"fig15.jpg","type":"GRAPHIC","id":"NTFILE6rPWhDP2U4Uiw3kT","market":"us","size":33677},{"description":"","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig16.jpg","primary":false,"translateUrl":"","linkName":"fig16.jpg","type":"GRAPHIC","id":"NTFILE64jgvHnnsXFVodpV","market":"us","size":50449},{"description":"","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig17.jpg","primary":false,"translateUrl":"","linkName":"fig17.jpg","type":"GRAPHIC","id":"NTFILEB7vkN8Vyh2w6Mj15","market":"us","size":19564},{"description":"","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig18.jpg","primary":false,"translateUrl":"","linkName":"fig18.jpg","type":"GRAPHIC","id":"NTFILE6QBPRgrR37tnwYUm","market":"us","size":67679},{"description":"","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig19a.jpg","primary":false,"translateUrl":"","linkName":"fig19a.jpg","type":"GRAPHIC","id":"NTFILEDe2MHpGSvgNSNQZe","market":"us","size":57015},{"description":"","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig19b.jpg","primary":false,"translateUrl":"","linkName":"fig19b.jpg","type":"GRAPHIC","id":"NTFILEGR2tQNqhJMbuVT1A","market":"us","size":52801},{"description":"","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/fig20.jpg","primary":false,"translateUrl":"","linkName":"fig20.jpg","type":"GRAPHIC","id":"NTFILEFaC3Jk94odzRonEJ","market":"us","size":66207},{"description":"","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/logo.jpg","primary":false,"translateUrl":"","linkName":"logo.jpg","type":"GRAPHIC","id":"NTFILECCj69oFJ8JBXwKuZ","market":"us","size":13672},{"description":"","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/neoantigen.jpg","primary":false,"translateUrl":"","linkName":"neoantigen.jpg","type":"GRAPHIC","id":"NTFILEFpvWNMnCC4yDGKS8","market":"us","size":59272},{"description":"","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/productdevelopment.jpg","primary":false,"translateUrl":"","linkName":"productdevelopment.jpg","type":"GRAPHIC","id":"NTFILE7n4CphWCsFroV152","market":"us","size":39604},{"description":"","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/stratambition.jpg","primary":false,"translateUrl":"","linkName":"stratambition.jpg","type":"GRAPHIC","id":"NTFILE7zuJ3LnnfXU6k2xD","market":"us","size":37630},{"description":"","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure20.jpg","primary":false,"translateUrl":"","linkName":"wfigure20.jpg","type":"GRAPHIC","id":"NTFILE8e3ptGaCbwVZRiUq","market":"us","size":34197},{"description":"","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure21.jpg","primary":false,"translateUrl":"","linkName":"wfigure21.jpg","type":"GRAPHIC","id":"NTFILE37YY234jHcCRMqs6","market":"us","size":24857},{"description":"","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure22.jpg","primary":false,"translateUrl":"","linkName":"wfigure22.jpg","type":"GRAPHIC","id":"NTFILE613SXVuWzwgu8kZ8","market":"us","size":55258},{"description":"","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure23.jpg","primary":false,"translateUrl":"","linkName":"wfigure23.jpg","type":"GRAPHIC","id":"NTFILE6HG5hg9HdQZDR2VL","market":"us","size":54666},{"description":"","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure24.jpg","primary":false,"translateUrl":"","linkName":"wfigure24.jpg","type":"GRAPHIC","id":"NTFILE5Etj4ov3CYZVm2JX","market":"us","size":37568},{"description":"","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure25.jpg","primary":false,"translateUrl":"","linkName":"wfigure25.jpg","type":"GRAPHIC","id":"NTFILE9RdPGithcH9WRLHe","market":"us","size":34599},{"description":"","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure26.jpg","primary":false,"translateUrl":"","linkName":"wfigure26.jpg","type":"GRAPHIC","id":"NTFILEfmn2cyzK3XziPT6y","market":"us","size":17032},{"description":"","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure27.jpg","primary":false,"translateUrl":"","linkName":"wfigure27.jpg","type":"GRAPHIC","id":"NTFILEGZRdQfmqgJB2KBYJ","market":"us","size":39469},{"description":"","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure28.jpg","primary":false,"translateUrl":"","linkName":"wfigure28.jpg","type":"GRAPHIC","id":"NTFILEEEg9z8rgFttDF5am","market":"us","size":35069},{"description":"","seq":49,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure29.jpg","primary":false,"translateUrl":"","linkName":"wfigure29.jpg","type":"GRAPHIC","id":"NTFILE7qvBwmjnXdRLe4Fj","market":"us","size":75601},{"description":"","seq":50,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure30.jpg","primary":false,"translateUrl":"","linkName":"wfigure30.jpg","type":"GRAPHIC","id":"NTFILEHBbaLwjZBfxPR2HU","market":"us","size":97670},{"description":"","seq":51,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure31.jpg","primary":false,"translateUrl":"","linkName":"wfigure31.jpg","type":"GRAPHIC","id":"NTFILE3HC5zws9vrv2acJj","market":"us","size":57034},{"description":"","seq":52,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure32.jpg","primary":false,"translateUrl":"","linkName":"wfigure32.jpg","type":"GRAPHIC","id":"NTFILE8ykpHJFGTDnW1x62","market":"us","size":40860},{"description":"","seq":53,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure33.jpg","primary":false,"translateUrl":"","linkName":"wfigure33.jpg","type":"GRAPHIC","id":"NTFILE6bs49jzLUUt6TxAc","market":"us","size":18876},{"description":"","seq":54,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure34.jpg","primary":false,"translateUrl":"","linkName":"wfigure34.jpg","type":"GRAPHIC","id":"NTFILE3ixESzfjeXmSJeMx","market":"us","size":20944},{"description":"","seq":55,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure35.jpg","primary":false,"translateUrl":"","linkName":"wfigure35.jpg","type":"GRAPHIC","id":"NTFILE3HtUw1Dm2Wh4z9W7","market":"us","size":18842},{"description":"","seq":56,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure36.jpg","primary":false,"translateUrl":"","linkName":"wfigure36.jpg","type":"GRAPHIC","id":"NTFILE6kk5Vn6LHs1Hekhx","market":"us","size":25243},{"description":"","seq":57,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure37.jpg","primary":false,"translateUrl":"","linkName":"wfigure37.jpg","type":"GRAPHIC","id":"NTFILE9c7JoAYBu7kA4fcW","market":"us","size":29777},{"description":"","seq":58,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure38.jpg","primary":false,"translateUrl":"","linkName":"wfigure38.jpg","type":"GRAPHIC","id":"NTFILEFortJdbzRLwRgHMR","market":"us","size":59749},{"description":"","seq":59,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure39.jpg","primary":false,"translateUrl":"","linkName":"wfigure39.jpg","type":"GRAPHIC","id":"NTFILEDxD4GjPDhJHkvrCW","market":"us","size":26353},{"description":"","seq":60,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure40.jpg","primary":false,"translateUrl":"","linkName":"wfigure40.jpg","type":"GRAPHIC","id":"NTFILE8HjGuLuP1AAKVbV4","market":"us","size":18966},{"description":"","seq":61,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure41.jpg","primary":false,"translateUrl":"","linkName":"wfigure41.jpg","type":"GRAPHIC","id":"NTFILE21T7r1y74VZoZyQA","market":"us","size":26848},{"description":"","seq":62,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure42.jpg","primary":false,"translateUrl":"","linkName":"wfigure42.jpg","type":"GRAPHIC","id":"NTFILEBHNSq421nty3p5VE","market":"us","size":46280},{"description":"","seq":63,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure43.jpg","primary":false,"translateUrl":"","linkName":"wfigure43.jpg","type":"GRAPHIC","id":"NTFILEEn4priTokdiB5Ar4","market":"us","size":55727},{"description":"","seq":64,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure44.jpg","primary":false,"translateUrl":"","linkName":"wfigure44.jpg","type":"GRAPHIC","id":"NTFILE595XFqk2VXDGskup","market":"us","size":39962},{"description":"","seq":65,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/wfigure45.jpg","primary":false,"translateUrl":"","linkName":"wfigure45.jpg","type":"GRAPHIC","id":"NTFILE6upyehUCrQKZu7GX","market":"us","size":18470}],"type_name":"Financial Report","type_name_en":"Financial Report","titleTypeEn":"Annual Report","us_type":"财务报告","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"Annual Report","pubTime":"2025-04-01 12:00","pubTimestamp":1743480000,"title_zh":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19179281","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925006763-EVAX","pdf_url":"","pub_time":1738102167000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"EVAX","title":"Form CORRESP - Correspondence","titleType":"Correspondence","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1828253/0001104659-25-006763-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006763/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILEHAJEpE2dQxjbmKm8","market":"us","size":9967},{"description":"GRAPHIC","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006763/tm2427973d9_correspimg001.jpg","primary":false,"translateUrl":"","linkName":"tm2427973d9_correspimg001.jpg","type":"GRAPHIC","id":"NTFILEHLMG6mZmQ9BnXNNC","market":"us","size":10597}],"type_name":"Transaction Related","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"交易披露","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"Correspondence","pubTime":"2025-01-29 06:09","pubTimestamp":1738102167,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19082994","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925006720-EVAX","pdf_url":"","pub_time":1738040400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","symbol":"EVAX","title":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","titleType":"[Amend]Public Prospectus","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/0001104659-25-006720-index.htm","us_notice_code":"Form F-1/A","us_title_en":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"F-1/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/tm2427973-7_f1a.htm","primary":true,"translateUrl":"","linkName":"tm2427973-7_f1a.htm","type":"F-1/A","id":"NTFILEDwhauwfnSg8xtK9A","market":"us","size":2382147},{"description":"EXHIBIT 1.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/tm2427973d8_ex1-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d8_ex1-1.htm","type":"EX-1.1","id":"NTFILEECAkyvmnitHknHY3","market":"us","size":99017},{"description":"EXHIBIT 10.18","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/tm2427973d8_ex10-18.htm","primary":false,"translateUrl":"","linkName":"tm2427973d8_ex10-18.htm","type":"EX-10.18","id":"NTFILEDyJVs349h7e6DDyU","market":"us","size":245001},{"description":"EXHIBIT 23.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/tm2427973d8_ex23-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d8_ex23-1.htm","type":"EX-23.1","id":"NTFILE9YiLbW8YcHd69nmU","market":"us","size":2219},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_antibody-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_antibody-4c.jpg","type":"GRAPHIC","id":"NTFILEFGgic4nhnSDaLTR9","market":"us","size":20090},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_bestranked-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_bestranked-4c.jpg","type":"GRAPHIC","id":"NTFILEJ7s2bCe8WK3PK4Sa","market":"us","size":36851},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_changetrg-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_changetrg-4c.jpg","type":"GRAPHIC","id":"NTFILE7M8Z32QHvHZvVyMd","market":"us","size":51187},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_killing-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_killing-4c.jpg","type":"GRAPHIC","id":"NTFILE7P3ZhTobbGFc1EJx","market":"us","size":65238},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_patient-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_patient-4c.jpg","type":"GRAPHIC","id":"NTFILE5aQurF6uPUgd5aYE","market":"us","size":67682},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_preexisting-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_preexisting-4c.jpg","type":"GRAPHIC","id":"NTFILEBVfPixfwJSFU1BKs","market":"us","size":81117},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_sarsgenome-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_sarsgenome-4c.jpg","type":"GRAPHIC","id":"NTFILE4HYaGCSqJWNbMuY3","market":"us","size":38363},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_sfupbmc-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_sfupbmc-4c.jpg","type":"GRAPHIC","id":"NTFILEHA8PiTx2GPfmEkNL","market":"us","size":83884},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/bc_splenocytes-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_splenocytes-4c.jpg","type":"GRAPHIC","id":"NTFILE2pAH11wmc8QsETqt","market":"us","size":38054},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_aiimmunology-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_aiimmunology-4clr.jpg","type":"GRAPHIC","id":"NTFILE6cddjTvaC5DH2rHe","market":"us","size":86486},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_cancer-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cancer-4c.jpg","type":"GRAPHIC","id":"NTFILECYKDyPWYdoYDGmjK","market":"us","size":60354},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_cancervaccines-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cancervaccines-4c.jpg","type":"GRAPHIC","id":"NTFILEBL4Zii8LQC4QsSUc","market":"us","size":38086},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_cd4cd8cells-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cd4cd8cells-4c.jpg","type":"GRAPHIC","id":"NTFILE8iJRtLvJrTYVtUsA","market":"us","size":74826},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_cells-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cells-4c.jpg","type":"GRAPHIC","id":"NTFILE3nCSFf2Aq3xBiKJS","market":"us","size":51252},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_datacuration-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_datacuration-4c.jpg","type":"GRAPHIC","id":"NTFILE8mpoFZMTrbNJHuLy","market":"us","size":55331},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_discovery-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_discovery-4c.jpg","type":"GRAPHIC","id":"NTFILEBPBJVQX3PzazMFr7","market":"us","size":160498},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_evx02-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_evx02-4clr.jpg","type":"GRAPHIC","id":"NTFILE44212sjY7L7dyBky","market":"us","size":95190},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_evxb1-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_evxb1-4c.jpg","type":"GRAPHIC","id":"NTFILEBCGtVRYdTFzAQePb","market":"us","size":62087},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_identification-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_identification-4c.jpg","type":"GRAPHIC","id":"NTFILEF6Y2fqZhXaFqvbRD","market":"us","size":82717},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_immun-bw.jpg","primary":false,"translateUrl":"","linkName":"fc_immun-bw.jpg","type":"GRAPHIC","id":"NTFILEDYndSHTJb2e56JkE","market":"us","size":95117},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_ngo265-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_ngo265-4c.jpg","type":"GRAPHIC","id":"NTFILE7TVacNwChRU5KCQ6","market":"us","size":174298},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_pioneerrna-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_pioneerrna-4c.jpg","type":"GRAPHIC","id":"NTFILEEwwtLvfeC3gU3eQw","market":"us","size":52253},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_proteins-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_proteins-4c.jpg","type":"GRAPHIC","id":"NTFILE2vqGkvmvRtspmqzv","market":"us","size":118887},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_screening-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_screening-4c.jpg","type":"GRAPHIC","id":"NTFILEAYdFEFb7dFFFEtim","market":"us","size":25983},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_stageofdevelop-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_stageofdevelop-4c.jpg","type":"GRAPHIC","id":"NTFILEDfV6p1xrVU7CDB3X","market":"us","size":80743},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_strategy-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_strategy-4c.jpg","type":"GRAPHIC","id":"NTFILE7cN3FUGYmqPwEvus","market":"us","size":132876},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_vaccinetreat-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_vaccinetreat-4clr.jpg","type":"GRAPHIC","id":"NTFILEEf7TcHte5tZAxNVc","market":"us","size":96229},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/fc_vehiclecontrol-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_vehiclecontrol-4c.jpg","type":"GRAPHIC","id":"NTFILEFLmDppMiNfZteQy8","market":"us","size":135671},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_abcessarea-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_abcessarea-4c.jpg","type":"GRAPHIC","id":"NTFILEARquVCWBENeE3Jzi","market":"us","size":37776},{"description":"GRAPHIC","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_auccfu-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_auccfu-4c.jpg","type":"GRAPHIC","id":"NTFILE7PazXtGZHPAL74aA","market":"us","size":62059},{"description":"GRAPHIC","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_bacteria-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_bacteria-4c.jpg","type":"GRAPHIC","id":"NTFILEA8Jej6jAKDKmMQGD","market":"us","size":154890},{"description":"GRAPHIC","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_cellinoculation-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_cellinoculation-4c.jpg","type":"GRAPHIC","id":"NTFILEG8nBnbVE3vP7GPLh","market":"us","size":92243},{"description":"GRAPHIC","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_clinical-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_clinical-4c.jpg","type":"GRAPHIC","id":"NTFILEAVQ2aneBu5nRYrXG","market":"us","size":106643},{"description":"GRAPHIC","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_empty-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_empty-4c.jpg","type":"GRAPHIC","id":"NTFILE47crc4PsKAz4GdYp","market":"us","size":35955},{"description":"GRAPHIC","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_emptyplasmid-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_emptyplasmid-4c.jpg","type":"GRAPHIC","id":"NTFILEr7BUKbVToh6kZ2ye","market":"us","size":73045},{"description":"GRAPHIC","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_halfmaxtiter-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_halfmaxtiter-4c.jpg","type":"GRAPHIC","id":"NTFILE9ti62UuYFeBY7X4B","market":"us","size":21103},{"description":"GRAPHIC","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_immunizations-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_immunizations-4c.jpg","type":"GRAPHIC","id":"NTFILE8eo3TBhK8RXf5ZJs","market":"us","size":25560},{"description":"GRAPHIC","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_kidneys-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_kidneys-4c.jpg","type":"GRAPHIC","id":"NTFILE8rzdKGtxD2zswuFX","market":"us","size":24535},{"description":"GRAPHIC","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_liuhugoanti-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_liuhugoanti-4c.jpg","type":"GRAPHIC","id":"NTFILE5zuvP6vNQBfcUEBb","market":"us","size":155237},{"description":"GRAPHIC","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_neoagspearson-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_neoagspearson-4c.jpg","type":"GRAPHIC","id":"NTFILE3x63DtbGuYt4zuJv","market":"us","size":70888},{"description":"GRAPHIC","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_pioneerscore-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_pioneerscore-bw.jpg","type":"GRAPHIC","id":"NTFILEDZ7y9EGdVMKnLv7Y","market":"us","size":45148},{"description":"GRAPHIC","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_postinfection-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_postinfection-4c.jpg","type":"GRAPHIC","id":"NTFILE2C11g9UEyKZAcLva","market":"us","size":22562},{"description":"GRAPHIC","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_postinfections-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_postinfections-4c.jpg","type":"GRAPHIC","id":"NTFILEDtQcgo7Sq34WFzn2","market":"us","size":277722},{"description":"GRAPHIC","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_prepost-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_prepost-bw.jpg","type":"GRAPHIC","id":"NTFILEEbZdopJC18q5iqwf","market":"us","size":59818},{"description":"GRAPHIC","seq":49,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_prepostfollow-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_prepostfollow-bw.jpg","type":"GRAPHIC","id":"NTFILECHc2TB4N7iogbe3g","market":"us","size":46903},{"description":"GRAPHIC","seq":50,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_shortlong-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_shortlong-4c.jpg","type":"GRAPHIC","id":"NTFILEAQM7RBCQHEhGsrb4","market":"us","size":75791},{"description":"GRAPHIC","seq":51,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_tumar-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumar-4c.jpg","type":"GRAPHIC","id":"NTFILE7YD8LdYeusWCkfLi","market":"us","size":59489},{"description":"GRAPHIC","seq":52,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_tumarvalume-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumarvalume-4c.jpg","type":"GRAPHIC","id":"NTFILEEv6MSAkgt2eV15p6","market":"us","size":78429},{"description":"GRAPHIC","seq":53,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lc_tumorvolume-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumorvolume-4c.jpg","type":"GRAPHIC","id":"NTFILEAZoDjxWy4HconG48","market":"us","size":128548},{"description":"GRAPHIC","seq":54,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/lg_evaxion-bwlr.jpg","primary":false,"translateUrl":"","linkName":"lg_evaxion-bwlr.jpg","type":"GRAPHIC","id":"NTFILE4gmDHNGpRXsn9N9k","market":"us","size":12591},{"description":"GRAPHIC","seq":55,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/tb_diseasestage-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_diseasestage-4c.jpg","type":"GRAPHIC","id":"NTFILEDSZzNAmYtMxTHHLr","market":"us","size":110882},{"description":"GRAPHIC","seq":56,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465925006720/tb_milestones-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_milestones-4c.jpg","type":"GRAPHIC","id":"NTFILE2ABPdnLidkwHEch7","market":"us","size":106338}],"type_name":"Recruitment Registration","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"招股注册","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[Amend]Public Prospectus","pubTime":"2025-01-28 13:00","pubTimestamp":1738040400,"title_zh":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18955015","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924129424-EVAX","pdf_url":"","pub_time":1734473379000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","symbol":"EVAX","title":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","titleType":"[Amend]Public Prospectus","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1828253/0001104659-24-129424-index.html","us_notice_code":"Form F-1/A","us_title_en":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"F-1/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973-5_f1a.htm","primary":true,"translateUrl":"","linkName":"tm2427973-5_f1a.htm","type":"F-1/A","id":"NTFILEHFbkVRVoHc8hjN2a","market":"us","size":2134845},{"description":"EXHIBIT 1.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d6_ex1-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d6_ex1-1.htm","type":"EX-1.1","id":"NTFILEGcr2aEFPELLo9FDg","market":"us","size":80940},{"description":"EXHIBIT 4.7","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d6_ex4-7.htm","primary":false,"translateUrl":"","linkName":"tm2427973d6_ex4-7.htm","type":"EX-4.7","id":"NTFILEDY7gQGux7xB5Fgs7","market":"us","size":94991},{"description":"EXHIBIT 4.8","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d6_ex4-8.htm","primary":false,"translateUrl":"","linkName":"tm2427973d6_ex4-8.htm","type":"EX-4.8","id":"NTFILEAFFbWrtXmzPeGx4L","market":"us","size":98903},{"description":"EXHIBIT 5.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d6_ex5-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d6_ex5-1.htm","type":"EX-5.1","id":"NTFILE9T3KZ9fk9no5qnsW","market":"us","size":49722},{"description":"EXHIBIT 10.18","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d6_ex10-18.htm","primary":false,"translateUrl":"","linkName":"tm2427973d6_ex10-18.htm","type":"EX-10.18","id":"NTFILEFEPaHPAMMTfe1qBQ","market":"us","size":206851},{"description":"EXHIBIT 23.1","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d6_ex23-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d6_ex23-1.htm","type":"EX-23.1","id":"NTFILE3AiNNh89CnzAupez","market":"us","size":2837},{"description":"EX-FILING FEES","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d6_ex-filingfees.htm","primary":false,"translateUrl":"","linkName":"tm2427973d6_ex-filingfees.htm","type":"EX-FILING FEES","id":"NTFILEuCbFY4PpuzS69Spn","market":"us","size":31190},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lg_evaxion-bwlr.jpg","primary":false,"translateUrl":"","linkName":"lg_evaxion-bwlr.jpg","type":"GRAPHIC","id":"NTFILEEedahQ2yDXCKcWB6","market":"us","size":12591},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_immun-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_immun-4c.jpg","type":"GRAPHIC","id":"NTFILEJ7giyNai96S8RZbf","market":"us","size":105452},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_strategy-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_strategy-4c.jpg","type":"GRAPHIC","id":"NTFILE4v6v9CgJXCiiJb4i","market":"us","size":132876},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tb_milestones-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_milestones-4c.jpg","type":"GRAPHIC","id":"NTFILE9pSBEYfJedksdrPG","market":"us","size":111477},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_aiimmunology-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_aiimmunology-4c.jpg","type":"GRAPHIC","id":"NTFILEAHiocjmeE6JNpVCx","market":"us","size":91703},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_cancer-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cancer-4c.jpg","type":"GRAPHIC","id":"NTFILEFrJDdUQPeih963ve","market":"us","size":60354},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_stageofdevelop-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_stageofdevelop-4c.jpg","type":"GRAPHIC","id":"NTFILE2Sbo6sahMnwmQjss","market":"us","size":92932},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_cells-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cells-4c.jpg","type":"GRAPHIC","id":"NTFILE662Lcmsnxz34aZSR","market":"us","size":51252},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_bestranked-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_bestranked-4c.jpg","type":"GRAPHIC","id":"NTFILE7uRDv353hqMxxy6s","market":"us","size":36851},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_cellinoculation-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_cellinoculation-4c.jpg","type":"GRAPHIC","id":"NTFILE2wRy7dYtxi9nhSfr","market":"us","size":92243},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_pioneerrna-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_pioneerrna-4c.jpg","type":"GRAPHIC","id":"NTFILE7NAd7WdrvSiuYXtc","market":"us","size":52253},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_cancervaccines-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cancervaccines-4c.jpg","type":"GRAPHIC","id":"NTFILEiRtJXgQdrkAC2e4y","market":"us","size":42428},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_vaccinetreat-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_vaccinetreat-4clr.jpg","type":"GRAPHIC","id":"NTFILE8piueyXDVqPiogps","market":"us","size":96229},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tb_diseasestage-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_diseasestage-4c.jpg","type":"GRAPHIC","id":"NTFILE4HTd88TrBErAEj6K","market":"us","size":110882},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_changetrg-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_changetrg-4c.jpg","type":"GRAPHIC","id":"NTFILE23LVACkMt6pZqNj3","market":"us","size":51187},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_prepost-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_prepost-bw.jpg","type":"GRAPHIC","id":"NTFILE9KEWt1J68Hdf6jU8","market":"us","size":59818},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_prepostfollow-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_prepostfollow-bw.jpg","type":"GRAPHIC","id":"NTFILEAYtPEbbFyGmJ1osN","market":"us","size":46903},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_pioneerscore-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_pioneerscore-bw.jpg","type":"GRAPHIC","id":"NTFILEGa1bDkUQ5ZkiuLcr","market":"us","size":45148},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_shortlong-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_shortlong-4c.jpg","type":"GRAPHIC","id":"NTFILEAXMpgKpewrsKwaHb","market":"us","size":75791},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_screening-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_screening-4c.jpg","type":"GRAPHIC","id":"NTFILEEBDZTkN8eFUjfJC9","market":"us","size":25983},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_sfupbmc-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_sfupbmc-4c.jpg","type":"GRAPHIC","id":"NTFILEc7PNMXFKdqV8hQ6d","market":"us","size":83884},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_cd4cd8cells-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cd4cd8cells-4c.jpg","type":"GRAPHIC","id":"NTFILE9STWFyji9VjQBvpP","market":"us","size":74826},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_neoagspearson-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_neoagspearson-4c.jpg","type":"GRAPHIC","id":"NTFILEH9TZcPquhTuQr8L8","market":"us","size":70888},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_patient-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_patient-4c.jpg","type":"GRAPHIC","id":"NTFILE2NBhf4fm87VM1SUu","market":"us","size":67682},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_preexisting-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_preexisting-4c.jpg","type":"GRAPHIC","id":"NTFILE7JWAhUuzKamR5kwu","market":"us","size":81117},{"description":"GRAPHIC","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_evx02-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_evx02-4clr.jpg","type":"GRAPHIC","id":"NTFILECwwfVreNPAoZwLFp","market":"us","size":95190},{"description":"GRAPHIC","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_empty-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_empty-4c.jpg","type":"GRAPHIC","id":"NTFILEBM3puaeFFya1MvQZ","market":"us","size":35955},{"description":"GRAPHIC","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_tumar-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumar-4c.jpg","type":"GRAPHIC","id":"NTFILEBN5KNUGcPbciN9FY","market":"us","size":59489},{"description":"GRAPHIC","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_tumarvalume-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumarvalume-4c.jpg","type":"GRAPHIC","id":"NTFILE788qJBf5aXFbyMrF","market":"us","size":78429},{"description":"GRAPHIC","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_emptyplasmid-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_emptyplasmid-4c.jpg","type":"GRAPHIC","id":"NTFILE2jNjhSrGFrnMYewa","market":"us","size":73045},{"description":"GRAPHIC","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_tumorvolume-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumorvolume-4c.jpg","type":"GRAPHIC","id":"NTFILEFsfiuNvaUoQzJNhg","market":"us","size":128548},{"description":"GRAPHIC","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_vehiclecontrol-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_vehiclecontrol-4c.jpg","type":"GRAPHIC","id":"NTFILE4D8Afnch9ewRHTL8","market":"us","size":135671},{"description":"GRAPHIC","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_clinical-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_clinical-4c.jpg","type":"GRAPHIC","id":"NTFILEEA9E8Zdqd4YxrjtJ","market":"us","size":106643},{"description":"GRAPHIC","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_liuhugoanti-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_liuhugoanti-4c.jpg","type":"GRAPHIC","id":"NTFILE8AGpJw97JH7mCTQ3","market":"us","size":155237},{"description":"GRAPHIC","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_datacuration-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_datacuration-4c.jpg","type":"GRAPHIC","id":"NTFILEEDupg46d2JwxDQUj","market":"us","size":55331},{"description":"GRAPHIC","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_discovery-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_discovery-4c.jpg","type":"GRAPHIC","id":"NTFILE9DUSESquJWHFg7Q3","market":"us","size":160498},{"description":"GRAPHIC","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_bacteria-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_bacteria-4c.jpg","type":"GRAPHIC","id":"NTFILE3SQrUoRCjwzHfrJc","market":"us","size":154890},{"description":"GRAPHIC","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_proteins-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_proteins-4c.jpg","type":"GRAPHIC","id":"NTFILEHFK9vZeg3XLGLwqt","market":"us","size":118887},{"description":"GRAPHIC","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_evxb1-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_evxb1-4c.jpg","type":"GRAPHIC","id":"NTFILEDcPGrgTqiKamunmh","market":"us","size":62087},{"description":"GRAPHIC","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_postinfection-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_postinfection-4c.jpg","type":"GRAPHIC","id":"NTFILE2wM7942j2eQz1ZNi","market":"us","size":22562},{"description":"GRAPHIC","seq":49,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_abcessarea-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_abcessarea-4c.jpg","type":"GRAPHIC","id":"NTFILEARwChL4UpRbBU1Js","market":"us","size":37776},{"description":"GRAPHIC","seq":50,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_halfmaxtiter-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_halfmaxtiter-4c.jpg","type":"GRAPHIC","id":"NTFILEJCDtBecyKYSCXvwn","market":"us","size":21103},{"description":"GRAPHIC","seq":51,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_kidneys-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_kidneys-4c.jpg","type":"GRAPHIC","id":"NTFILEB9dGonDHpXJot7PF","market":"us","size":24535},{"description":"GRAPHIC","seq":52,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_ngo265-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_ngo265-4c.jpg","type":"GRAPHIC","id":"NTFILE8dRMWGRuK4z24W1R","market":"us","size":174298},{"description":"GRAPHIC","seq":53,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_postinfections-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_postinfections-4c.jpg","type":"GRAPHIC","id":"NTFILE8vAabt89sFbWgWfK","market":"us","size":277722},{"description":"GRAPHIC","seq":54,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_auccfu-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_auccfu-4c.jpg","type":"GRAPHIC","id":"NTFILE4YrDyPfp3Y6wy8g7","market":"us","size":62059},{"description":"GRAPHIC","seq":55,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/lc_immunizations-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_immunizations-4c.jpg","type":"GRAPHIC","id":"NTFILE2PgiewTrBpEhXtZJ","market":"us","size":25560},{"description":"GRAPHIC","seq":56,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_splenocytes-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_splenocytes-4c.jpg","type":"GRAPHIC","id":"NTFILE5GJKzBMHdkXCna9S","market":"us","size":38054},{"description":"GRAPHIC","seq":57,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_killing-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_killing-4c.jpg","type":"GRAPHIC","id":"NTFILE7ZSY6QhnDRiA4o9R","market":"us","size":65238},{"description":"GRAPHIC","seq":58,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/fc_identification-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_identification-4c.jpg","type":"GRAPHIC","id":"NTFILEB49crWyd6jRCfPqG","market":"us","size":82717},{"description":"GRAPHIC","seq":59,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_sarsgenome-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_sarsgenome-4c.jpg","type":"GRAPHIC","id":"NTFILE2drZ6h2ghWpubhRb","market":"us","size":38363},{"description":"GRAPHIC","seq":60,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/bc_antibody-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_antibody-4c.jpg","type":"GRAPHIC","id":"NTFILEENzy9ZnQHiu9WSwZ","market":"us","size":20090},{"description":"GRAPHIC","seq":61,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d4_ex5-1img001.jpg","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex5-1img001.jpg","type":"GRAPHIC","id":"NTFILEJ82dznYiDmjurmKJ","market":"us","size":3052},{"description":"GRAPHIC","seq":62,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924129424/tm2427973d4_ex5-1img02.jpg","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex5-1img02.jpg","type":"GRAPHIC","id":"NTFILE4eaC59QNBU8QL6Hp","market":"us","size":763}],"type_name":"Recruitment Registration","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"招股注册","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[Amend]Public Prospectus","pubTime":"2024-12-18 06:09","pubTimestamp":1734473379,"title_zh":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18912079","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924125931-EVAX","pdf_url":"","pub_time":1733374800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","symbol":"EVAX","title":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","titleType":"[Amend]Public Prospectus","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/0001104659-24-125931-index.htm","us_notice_code":"Form F-1/A","us_title_en":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"F-1/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973-3_f1a.htm","primary":true,"translateUrl":"","linkName":"tm2427973-3_f1a.htm","type":"F-1/A","id":"NTFILE8c6FTVHcaVamyC1F","market":"us","size":2125418},{"description":"EXHIBIT 1.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex1-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex1-1.htm","type":"EX-1.1","id":"NTFILEGti8Zxxxy7R7mdRW","market":"us","size":80847},{"description":"EXHIBIT 4.7","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex4-7.htm","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex4-7.htm","type":"EX-4.7","id":"NTFILE8f3r31iKWgGzoUmM","market":"us","size":84482},{"description":"EXHIBIT 5.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex5-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex5-1.htm","type":"EX-5.1","id":"NTFILE5AvGpmTftPychQZt","market":"us","size":47767},{"description":"EXHIBIT 8.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex8-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex8-1.htm","type":"EX-8.1","id":"NTFILEQscBCUQER1FGQuW5","market":"us","size":25637},{"description":"EXHIBIT 10.18","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex10-18.htm","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex10-18.htm","type":"EX-10.18","id":"NTFILEGZUyq2bpGsUnkuWT","market":"us","size":204860},{"description":"EXHIBIT 23.1","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex23-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex23-1.htm","type":"EX-23.1","id":"NTFILE6eX44cdPs5LBB5Ko","market":"us","size":2847},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_antibody-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_antibody-4c.jpg","type":"GRAPHIC","id":"NTFILE7DJtam5fdRE7HxnZ","market":"us","size":20090},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_bestranked-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_bestranked-4c.jpg","type":"GRAPHIC","id":"NTFILEGUQaRPkqtuKeBNpZ","market":"us","size":36851},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_changetrg-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_changetrg-4c.jpg","type":"GRAPHIC","id":"NTFILEC9PmGwLGWs78TC74","market":"us","size":51187},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_killing-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_killing-4c.jpg","type":"GRAPHIC","id":"NTFILE236CxfDigdPWX1uf","market":"us","size":65238},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_patient-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_patient-4c.jpg","type":"GRAPHIC","id":"NTFILE2HMpSftCGwXpc81T","market":"us","size":67682},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_preexisting-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_preexisting-4c.jpg","type":"GRAPHIC","id":"NTFILEFRFokxY7TLhCnqn2","market":"us","size":81117},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_sarsgenome-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_sarsgenome-4c.jpg","type":"GRAPHIC","id":"NTFILE2LW3xVDB77zqiWDh","market":"us","size":38363},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_sfupbmc-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_sfupbmc-4c.jpg","type":"GRAPHIC","id":"NTFILE3ozGSXHpVbAMM25h","market":"us","size":83884},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/bc_splenocytes-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_splenocytes-4c.jpg","type":"GRAPHIC","id":"NTFILEFbyMkkmTuVLVbegW","market":"us","size":38054},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_aiimmunology-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_aiimmunology-4c.jpg","type":"GRAPHIC","id":"NTFILE9Ln63BkWF18SghNY","market":"us","size":91703},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_cancer-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cancer-4c.jpg","type":"GRAPHIC","id":"NTFILEB2wRrjpRoi3vGv7R","market":"us","size":60354},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_cancervaccines-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cancervaccines-4c.jpg","type":"GRAPHIC","id":"NTFILEFqjqAxbpvivYa5QW","market":"us","size":42428},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_cd4cd8cells-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cd4cd8cells-4c.jpg","type":"GRAPHIC","id":"NTFILE8PpWSJZbW26HqV8L","market":"us","size":74826},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_cells-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cells-4c.jpg","type":"GRAPHIC","id":"NTFILEBXk9MRYoLAaWhCMe","market":"us","size":51252},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_datacuration-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_datacuration-4c.jpg","type":"GRAPHIC","id":"NTFILEHnEAc4nwMcV81H6z","market":"us","size":55331},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_discovery-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_discovery-4c.jpg","type":"GRAPHIC","id":"NTFILEDNFwZurDiV2QE5bv","market":"us","size":160498},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_evx02-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_evx02-4clr.jpg","type":"GRAPHIC","id":"NTFILEFnCkBeanz7eAqXHb","market":"us","size":95190},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_evxb1-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_evxb1-4c.jpg","type":"GRAPHIC","id":"NTFILE6CamTJfzp2yoejNo","market":"us","size":62087},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_identification-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_identification-4c.jpg","type":"GRAPHIC","id":"NTFILEHfHukemGFCHGy7XA","market":"us","size":82717},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_immun-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_immun-4c.jpg","type":"GRAPHIC","id":"NTFILE2GyewdzkBnL4Ho2E","market":"us","size":105452},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_ngo265-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_ngo265-4c.jpg","type":"GRAPHIC","id":"NTFILEA1PAGf6Y7Z12FNJs","market":"us","size":174298},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_pioneerrna-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_pioneerrna-4c.jpg","type":"GRAPHIC","id":"NTFILEFCY34TjLd4YLPy1A","market":"us","size":52253},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_proteins-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_proteins-4c.jpg","type":"GRAPHIC","id":"NTFILE3SfAQ7BKmB6TkPyu","market":"us","size":118887},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_screening-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_screening-4c.jpg","type":"GRAPHIC","id":"NTFILE25FnsBgv9RV3BQdP","market":"us","size":25983},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_stageofdevelop-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_stageofdevelop-4c.jpg","type":"GRAPHIC","id":"NTFILE7yoaFFQCMcpBYWfi","market":"us","size":92932},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_strategy-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_strategy-4c.jpg","type":"GRAPHIC","id":"NTFILE6o8smKjMS118Y19n","market":"us","size":132876},{"description":"GRAPHIC","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_vaccinetreat-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_vaccinetreat-4clr.jpg","type":"GRAPHIC","id":"NTFILE73KXCRPGYQZrBhai","market":"us","size":96229},{"description":"GRAPHIC","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/fc_vehiclecontrol-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_vehiclecontrol-4c.jpg","type":"GRAPHIC","id":"NTFILEjpsR4kjV9aueu6h2","market":"us","size":135671},{"description":"GRAPHIC","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_abcessarea-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_abcessarea-4c.jpg","type":"GRAPHIC","id":"NTFILE7HNxmzo8CBDGc8Bh","market":"us","size":37776},{"description":"GRAPHIC","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_auccfu-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_auccfu-4c.jpg","type":"GRAPHIC","id":"NTFILE3vuSPHoMmG5YUp21","market":"us","size":62059},{"description":"GRAPHIC","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_bacteria-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_bacteria-4c.jpg","type":"GRAPHIC","id":"NTFILE8ccQMUNte2zkAowa","market":"us","size":154890},{"description":"GRAPHIC","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_cellinoculation-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_cellinoculation-4c.jpg","type":"GRAPHIC","id":"NTFILEFCLfxS8nB8NNerzG","market":"us","size":92243},{"description":"GRAPHIC","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_clinical-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_clinical-4c.jpg","type":"GRAPHIC","id":"NTFILEEShoTzNvmerN21Sr","market":"us","size":106643},{"description":"GRAPHIC","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_empty-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_empty-4c.jpg","type":"GRAPHIC","id":"NTFILE4TDGddLsGTpwvjhi","market":"us","size":35955},{"description":"GRAPHIC","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_emptyplasmid-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_emptyplasmid-4c.jpg","type":"GRAPHIC","id":"NTFILEGiez1mi3kSosp4oZ","market":"us","size":73045},{"description":"GRAPHIC","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_halfmaxtiter-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_halfmaxtiter-4c.jpg","type":"GRAPHIC","id":"NTFILE2Y1Qqsq1kJw77z9U","market":"us","size":21103},{"description":"GRAPHIC","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_immunizations-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_immunizations-4c.jpg","type":"GRAPHIC","id":"NTFILEG98WEiq7vVijwGpE","market":"us","size":25560},{"description":"GRAPHIC","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_kidneys-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_kidneys-4c.jpg","type":"GRAPHIC","id":"NTFILECoakZq4ztY7wFH6R","market":"us","size":24535},{"description":"GRAPHIC","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_liuhugoanti-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_liuhugoanti-4c.jpg","type":"GRAPHIC","id":"NTFILEDkZ9E9FdyEzkGPUq","market":"us","size":155237},{"description":"GRAPHIC","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_neoagspearson-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_neoagspearson-4c.jpg","type":"GRAPHIC","id":"NTFILEB436J7gouSqRuno3","market":"us","size":70888},{"description":"GRAPHIC","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_pioneerscore-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_pioneerscore-bw.jpg","type":"GRAPHIC","id":"NTFILEJ3jN8gmGLBnj3ij3","market":"us","size":45148},{"description":"GRAPHIC","seq":49,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_postinfection-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_postinfection-4c.jpg","type":"GRAPHIC","id":"NTFILEHSVALywNfHdpisRt","market":"us","size":22562},{"description":"GRAPHIC","seq":50,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_postinfections-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_postinfections-4c.jpg","type":"GRAPHIC","id":"NTFILEJ5HcNwSqR9VBftEo","market":"us","size":277722},{"description":"GRAPHIC","seq":51,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_prepost-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_prepost-bw.jpg","type":"GRAPHIC","id":"NTFILE7LERRT4W6DBFb9yb","market":"us","size":59818},{"description":"GRAPHIC","seq":52,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_prepostfollow-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_prepostfollow-bw.jpg","type":"GRAPHIC","id":"NTFILE2FwUGUuh2dp5aifg","market":"us","size":46903},{"description":"GRAPHIC","seq":53,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_shortlong-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_shortlong-4c.jpg","type":"GRAPHIC","id":"NTFILEFQZ4B7MSN2cg4DcZ","market":"us","size":75791},{"description":"GRAPHIC","seq":54,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_tumar-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumar-4c.jpg","type":"GRAPHIC","id":"NTFILE9xYjg1Fdtn7yBjLE","market":"us","size":59489},{"description":"GRAPHIC","seq":55,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_tumarvalume-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumarvalume-4c.jpg","type":"GRAPHIC","id":"NTFILEDcxtG7JhkmWZJt68","market":"us","size":78429},{"description":"GRAPHIC","seq":56,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lc_tumorvolume-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumorvolume-4c.jpg","type":"GRAPHIC","id":"NTFILEFW7Xzp2ymWPWekum","market":"us","size":128548},{"description":"GRAPHIC","seq":57,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/lg_evaxion-bwlr.jpg","primary":false,"translateUrl":"","linkName":"lg_evaxion-bwlr.jpg","type":"GRAPHIC","id":"NTFILEHsQsmvFG7cvjKfvH","market":"us","size":12591},{"description":"GRAPHIC","seq":58,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tb_diseasestage-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_diseasestage-4c.jpg","type":"GRAPHIC","id":"NTFILE4ovVSMBaKwwJpLmU","market":"us","size":110882},{"description":"GRAPHIC","seq":59,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tb_milestones-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_milestones-4c.jpg","type":"GRAPHIC","id":"NTFILE4JYakCidfreYgdpW","market":"us","size":111477},{"description":"GRAPHIC","seq":60,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex5-1img001.jpg","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex5-1img001.jpg","type":"GRAPHIC","id":"NTFILE8n5AFUQheayytaLT","market":"us","size":3052},{"description":"GRAPHIC","seq":61,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex5-1img02.jpg","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex5-1img02.jpg","type":"GRAPHIC","id":"NTFILEaS4JjaV6Prv3hrHm","market":"us","size":763},{"description":"GRAPHIC","seq":62,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex8-1img001.jpg","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex8-1img001.jpg","type":"GRAPHIC","id":"NTFILE3gJtdu1UZ72qQKcs","market":"us","size":3016},{"description":"GRAPHIC","seq":63,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924125931/tm2427973d4_ex8-1img002.jpg","primary":false,"translateUrl":"","linkName":"tm2427973d4_ex8-1img002.jpg","type":"GRAPHIC","id":"NTFILE6FqL4kGMop5PCcPW","market":"us","size":785}],"type_name":"Recruitment Registration","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"招股注册","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[Amend]Public Prospectus","pubTime":"2024-12-05 13:00","pubTimestamp":1733374800,"title_zh":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18847784","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924120159-EVAX","pdf_url":"","pub_time":1731906000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1 - Registration statement for certain foreign private issuers","symbol":"EVAX","title":"Form F-1 - Registration statement for certain foreign private issuers","titleType":"Public Prospectus","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/0001104659-24-120159-index.htm","us_notice_code":"Form F-1","us_title_en":"Form F-1 - Registration statement for certain foreign private issuers","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"F-1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/tm2427973-1_f1.htm","primary":true,"translateUrl":"","linkName":"tm2427973-1_f1.htm","type":"F-1","id":"NTFILE6vKcxBVCdTmz79mr","market":"us","size":2108146},{"description":"EXHIBIT 23.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/tm2427973d2_23-1.htm","primary":false,"translateUrl":"","linkName":"tm2427973d2_23-1.htm","type":"EX-23.1","id":"NTFILE9W3rgkemDkcM9qNv","market":"us","size":2067},{"description":"EX-FILING FEES","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/tm2427973d2_ex-filingfees.htm","primary":false,"translateUrl":"","linkName":"tm2427973d2_ex-filingfees.htm","type":"EX-FILING FEES","id":"NTFILE8wRf26b8Rq3iqaZU","market":"us","size":27517},{"description":"GRAPHIC","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lg_evaxion-bwlr.jpg","primary":false,"translateUrl":"","linkName":"lg_evaxion-bwlr.jpg","type":"GRAPHIC","id":"NTFILEDmnvJX2qt1dfBLbR","market":"us","size":12591},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_immun-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_immun-4c.jpg","type":"GRAPHIC","id":"NTFILECssWTcFSdy9uTLHJ","market":"us","size":105452},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_strategy-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_strategy-4c.jpg","type":"GRAPHIC","id":"NTFILEAp6wKiENvgszmfHP","market":"us","size":132876},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/tb_milestones-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_milestones-4c.jpg","type":"GRAPHIC","id":"NTFILE7D8xqcaTyowQJgxf","market":"us","size":111477},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_aiimmunology-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_aiimmunology-4c.jpg","type":"GRAPHIC","id":"NTFILEGSGVav2KHy4Si1gW","market":"us","size":91703},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_cancer-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cancer-4c.jpg","type":"GRAPHIC","id":"NTFILE2BHG5fH253J9KkKa","market":"us","size":60354},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_stageofdevelop-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_stageofdevelop-4c.jpg","type":"GRAPHIC","id":"NTFILE9e4rKun2g3UFUxaR","market":"us","size":92932},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_cells-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cells-4c.jpg","type":"GRAPHIC","id":"NTFILEGNbc41RqxnJvQMB6","market":"us","size":51252},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_bestranked-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_bestranked-4c.jpg","type":"GRAPHIC","id":"NTFILEHD35eUmMm9AsSvMG","market":"us","size":36851},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_cellinoculation-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_cellinoculation-4c.jpg","type":"GRAPHIC","id":"NTFILE5ZtENtiTo6AraSzV","market":"us","size":92243},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_pioneerrna-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_pioneerrna-4c.jpg","type":"GRAPHIC","id":"NTFILEB92S58ZRRpfCfYb4","market":"us","size":52253},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_cancervaccines-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cancervaccines-4c.jpg","type":"GRAPHIC","id":"NTFILEDRWVBBmCnmbHfrzr","market":"us","size":42428},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_vaccinetreat-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_vaccinetreat-4clr.jpg","type":"GRAPHIC","id":"NTFILE4Mnb1hTdP8twTXJu","market":"us","size":96229},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/tb_diseasestage-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_diseasestage-4c.jpg","type":"GRAPHIC","id":"NTFILE6aZgikt9jRUMyKef","market":"us","size":110882},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_changetrg-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_changetrg-4c.jpg","type":"GRAPHIC","id":"NTFILE5ywbu8zeXdfBNUVx","market":"us","size":51187},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_prepost-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_prepost-bw.jpg","type":"GRAPHIC","id":"NTFILE3KZ7MGjwZMahvD1T","market":"us","size":59818},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_prepostfollow-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_prepostfollow-bw.jpg","type":"GRAPHIC","id":"NTFILE4tHnKtRcUoacvove","market":"us","size":46903},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_pioneerscore-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_pioneerscore-bw.jpg","type":"GRAPHIC","id":"NTFILE9PFG5pkhXG3hBaTY","market":"us","size":45148},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_shortlong-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_shortlong-4c.jpg","type":"GRAPHIC","id":"NTFILE6u8jCc25qMDYqb7c","market":"us","size":75791},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_screening-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_screening-4c.jpg","type":"GRAPHIC","id":"NTFILE75qVXYrgh9TuDfhj","market":"us","size":25983},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_sfupbmc-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_sfupbmc-4c.jpg","type":"GRAPHIC","id":"NTFILEFumJkgb8cXhC2Ley","market":"us","size":83884},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_cd4cd8cells-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_cd4cd8cells-4c.jpg","type":"GRAPHIC","id":"NTFILE6GdTePDf4f7Mqycy","market":"us","size":74826},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_neoagspearson-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_neoagspearson-4c.jpg","type":"GRAPHIC","id":"NTFILEBJQLeMSQkxzSZHvL","market":"us","size":70888},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_patient-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_patient-4c.jpg","type":"GRAPHIC","id":"NTFILEAocBRTM1Zekd4of7","market":"us","size":67682},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_preexisting-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_preexisting-4c.jpg","type":"GRAPHIC","id":"NTFILE8MyASASewEBnE3qd","market":"us","size":81117},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_evx02-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_evx02-4clr.jpg","type":"GRAPHIC","id":"NTFILEHswPe8o9E5c2WzdA","market":"us","size":95190},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_empty-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_empty-4c.jpg","type":"GRAPHIC","id":"NTFILEHsnspFrDAzf1MMK1","market":"us","size":35955},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_tumar-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumar-4c.jpg","type":"GRAPHIC","id":"NTFILE143RKaKGzRNr5GrE","market":"us","size":59489},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_tumarvalume-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumarvalume-4c.jpg","type":"GRAPHIC","id":"NTFILE7D9KdTn5Kbn4RNLg","market":"us","size":78429},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_emptyplasmid-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_emptyplasmid-4c.jpg","type":"GRAPHIC","id":"NTFILEG4SgtbGeYSQLnNRn","market":"us","size":73045},{"description":"GRAPHIC","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_tumorvolume-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_tumorvolume-4c.jpg","type":"GRAPHIC","id":"NTFILE6x6x8Y3iq66wwRRc","market":"us","size":128548},{"description":"GRAPHIC","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_vehiclecontrol-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_vehiclecontrol-4c.jpg","type":"GRAPHIC","id":"NTFILECFGoujMEwpxJLRhU","market":"us","size":135671},{"description":"GRAPHIC","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_clinical-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_clinical-4c.jpg","type":"GRAPHIC","id":"NTFILEA6zw4zbcXRHesBXQ","market":"us","size":106643},{"description":"GRAPHIC","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_liuhugoanti-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_liuhugoanti-4c.jpg","type":"GRAPHIC","id":"NTFILE3HH5qwpc8jsVtU3D","market":"us","size":155237},{"description":"GRAPHIC","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_datacuration-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_datacuration-4c.jpg","type":"GRAPHIC","id":"NTFILE6Z5cjZraki4Fk8ub","market":"us","size":55331},{"description":"GRAPHIC","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_discovery-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_discovery-4c.jpg","type":"GRAPHIC","id":"NTFILE5Man5ykK9YUkUP6M","market":"us","size":160498},{"description":"GRAPHIC","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_bacteria-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_bacteria-4c.jpg","type":"GRAPHIC","id":"NTFILE4FUF3JZdQELWygkv","market":"us","size":154890},{"description":"GRAPHIC","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_proteins-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_proteins-4c.jpg","type":"GRAPHIC","id":"NTFILEFwAyPnzQFDqpyMSM","market":"us","size":118887},{"description":"GRAPHIC","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_evxb1-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_evxb1-4c.jpg","type":"GRAPHIC","id":"NTFILEBbRWSVxmsgXY48aU","market":"us","size":62087},{"description":"GRAPHIC","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_postinfection-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_postinfection-4c.jpg","type":"GRAPHIC","id":"NTFILEHrFz42sK1wAVpFsY","market":"us","size":22562},{"description":"GRAPHIC","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_abcessarea-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_abcessarea-4c.jpg","type":"GRAPHIC","id":"NTFILEDrCbQB1uEtJvfhUw","market":"us","size":37776},{"description":"GRAPHIC","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_halfmaxtiter-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_halfmaxtiter-4c.jpg","type":"GRAPHIC","id":"NTFILEFNbZnUDPjcugkxJR","market":"us","size":21103},{"description":"GRAPHIC","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_kidneys-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_kidneys-4c.jpg","type":"GRAPHIC","id":"NTFILEG7u3F81kN72WSskY","market":"us","size":24535},{"description":"GRAPHIC","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_ngo265-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_ngo265-4c.jpg","type":"GRAPHIC","id":"NTFILE6dwaUyH9VcSary8D","market":"us","size":174298},{"description":"GRAPHIC","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_postinfections-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_postinfections-4c.jpg","type":"GRAPHIC","id":"NTFILEB868QThtNH84F2xE","market":"us","size":277722},{"description":"GRAPHIC","seq":49,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_auccfu-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_auccfu-4c.jpg","type":"GRAPHIC","id":"NTFILE5jS7Q4eMBs7tQzdL","market":"us","size":62059},{"description":"GRAPHIC","seq":50,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/lc_immunizations-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_immunizations-4c.jpg","type":"GRAPHIC","id":"NTFILEAmQ3m5Ysp6Wa6tA7","market":"us","size":25560},{"description":"GRAPHIC","seq":51,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_splenocytes-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_splenocytes-4c.jpg","type":"GRAPHIC","id":"NTFILEDMpwtAy7Pco9Pf5a","market":"us","size":38054},{"description":"GRAPHIC","seq":52,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_killing-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_killing-4c.jpg","type":"GRAPHIC","id":"NTFILE4npECrgkPZhDuHZz","market":"us","size":65238},{"description":"GRAPHIC","seq":53,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/fc_identification-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_identification-4c.jpg","type":"GRAPHIC","id":"NTFILEFqQgXWjMAY5UM2Pr","market":"us","size":82717},{"description":"GRAPHIC","seq":54,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_sarsgenome-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_sarsgenome-4c.jpg","type":"GRAPHIC","id":"NTFILEC1uTD4uURFxgLkLG","market":"us","size":38363},{"description":"GRAPHIC","seq":55,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924120159/bc_antibody-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_antibody-4c.jpg","type":"GRAPHIC","id":"NTFILE5TzpuZ5TTz4Wc21a","market":"us","size":20090}],"type_name":"Recruitment Registration","type_name_en":"Recruitment Registration","titleTypeEn":"Public Prospectus","us_type":"招股注册","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"Public Prospectus","pubTime":"2024-11-18 13:00","pubTimestamp":1731906000,"title_zh":"Form F-1 - Registration statement for certain foreign private issuers","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18834979","market":"us","labels":[],"media":"sec.gov","original_id":"AN117266124005086-EVAX","pdf_url":"","pub_time":1731560400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SC 13G - Statement of Beneficial Ownership by Certain Investors","symbol":"EVAX","title":"Form SC 13G - Statement of Beneficial Ownership by Certain Investors","titleType":"Beneficial Ownership Change","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1828253/000117266124005086/0001172661-24-005086-index.htm","us_notice_code":"Form SC 13G","us_title_en":"Form SC 13G - Statement of Beneficial Ownership by Certain Investors","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1601086/000117266124005086/armistice-evax093024.htm","primary":true,"translateUrl":"","linkName":"armistice-evax093024.htm","type":"SC 13G","id":"NTFILEEAGZBFTEnAE6WuQD","market":"us","size":88943}],"type_name":"Transaction Related","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"交易披露","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"Beneficial Ownership Change","pubTime":"2024-11-14 13:00","pubTimestamp":1731560400,"title_zh":"Form SC 13G - Statement of Beneficial Ownership by Certain Investors","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18804221","market":"us","labels":[],"media":"sec.gov","original_id":"AN89534524000536-EVAX","pdf_url":"","pub_time":1730927397000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","symbol":"EVAX","title":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","titleType":"Beneficial Ownership Change","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1828253/0000895345-24-000536-index.html","us_notice_code":"Form SC 13G/A","us_title_en":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/310158/000089534524000536/ff4087100_13ga1-evaxion.htm","primary":true,"translateUrl":"","linkName":"ff4087100_13ga1-evaxion.htm","type":"SC 13G/A","id":"NTFILE23yVTAfkoSYEopVV","market":"us","size":141041}],"type_name":"Transaction Related","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"交易披露","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"Beneficial Ownership Change","pubTime":"2024-11-07 05:09","pubTimestamp":1730927397,"title_zh":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18634495","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924091291-EVAX","pdf_url":"","pub_time":1724126400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"EVAX","title":"Form CORRESP - Correspondence","titleType":"Correspondence","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091291/0001104659-24-091291-index.htm","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091291/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILE7nnGGKYTi7iSQVhj","market":"us","size":9819},{"description":"GRAPHIC","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091291/tm2413457d8_correspimg001.jpg","primary":false,"translateUrl":"","linkName":"tm2413457d8_correspimg001.jpg","type":"GRAPHIC","id":"NTFILE3DN6Nj8mjagXE7p5","market":"us","size":10597}],"type_name":"Transaction Related","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"交易披露","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"Correspondence","pubTime":"2024-08-20 12:00","pubTimestamp":1724126400,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18494052","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924091081-EVAX","pdf_url":"","pub_time":1724126400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","symbol":"EVAX","title":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","titleType":"[Amend]Public Prospectus","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091081/0001104659-24-091081-index.htm","us_notice_code":"Form F-1/A","us_title_en":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"F-1/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091081/tm2413457-6_f1a.htm","primary":true,"translateUrl":"","linkName":"tm2413457-6_f1a.htm","type":"F-1/A","id":"NTFILEByREWwxpwbAmEB1F","market":"us","size":1113618},{"description":"EXHIBIT 23.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091081/tm2413457d7_ex23-1.htm","primary":false,"translateUrl":"","linkName":"tm2413457d7_ex23-1.htm","type":"EX-23.1","id":"NTFILEEberbEKUBjNg88Mi","market":"us","size":2527},{"description":"GRAPHIC","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091081/lg_evaxionaiimmunology-bwlr.jpg","primary":false,"translateUrl":"","linkName":"lg_evaxionaiimmunology-bwlr.jpg","type":"GRAPHIC","id":"NTFILEBgFXmCS2ieFqcpgX","market":"us","size":10983},{"description":"GRAPHIC","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091081/tb_stageofdev-4clr.jpg","primary":false,"translateUrl":"","linkName":"tb_stageofdev-4clr.jpg","type":"GRAPHIC","id":"NTFILE7Dj72WjziHqh2eYH","market":"us","size":82669},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091081/tb_screeningpembro-4clr.jpg","primary":false,"translateUrl":"","linkName":"tb_screeningpembro-4clr.jpg","type":"GRAPHIC","id":"NTFILE47WqoLygmeuuJY58","market":"us","size":31981},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091081/tb_treatmentgroups-4clr.jpg","primary":false,"translateUrl":"","linkName":"tb_treatmentgroups-4clr.jpg","type":"GRAPHIC","id":"NTFILEJ13gw3R93SVjM9uW","market":"us","size":43283},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924091081/bc_ngstrains-4clr.jpg","primary":false,"translateUrl":"","linkName":"bc_ngstrains-4clr.jpg","type":"GRAPHIC","id":"NTFILE3Z5RUPqpBxE21XFJ","market":"us","size":61843}],"type_name":"Recruitment Registration","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"招股注册","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[Amend]Public Prospectus","pubTime":"2024-08-20 12:00","pubTimestamp":1724126400,"title_zh":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18635050","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924081497-EVAX","pdf_url":"","pub_time":1721620800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"EVAX","title":"Form CORRESP - Correspondence","titleType":"Correspondence","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081497/0001104659-24-081497-index.htm","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081497/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILEBM4Agr6vSJ71RrRN","market":"us","size":20303},{"description":"GRAPHIC","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081497/tm2413457d5_correspimg002.jpg","primary":false,"translateUrl":"","linkName":"tm2413457d5_correspimg002.jpg","type":"GRAPHIC","id":"NTFILE2bdkU2kGCiv4o5CG","market":"us","size":3170},{"description":"GRAPHIC","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081497/tm2413457d5_correspimg001.jpg","primary":false,"translateUrl":"","linkName":"tm2413457d5_correspimg001.jpg","type":"GRAPHIC","id":"NTFILE9QkNsaGb1dbiaaxh","market":"us","size":7076}],"type_name":"Transaction Related","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"交易披露","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"Correspondence","pubTime":"2024-07-22 12:00","pubTimestamp":1721620800,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18392269","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924081492-EVAX","pdf_url":"","pub_time":1721620800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","symbol":"EVAX","title":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","titleType":"[Amend]Public Prospectus","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/0001104659-24-081492-index.htm","us_notice_code":"Form F-1/A","us_title_en":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":null,"gpt_en_title":null,"attachments":[{"description":"F-1/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/tm2413457-3_f1a.htm","primary":true,"translateUrl":"","linkName":"tm2413457-3_f1a.htm","type":"F-1/A","id":"NTFILE95bnFmcWjUs6Aqh7","market":"us","size":1103606},{"description":"EXHIBIT 5.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/tm2413457d4_ex5-1.htm","primary":false,"translateUrl":"","linkName":"tm2413457d4_ex5-1.htm","type":"EX-5.1","id":"NTFILE3k2KFQaDTcGy9gXm","market":"us","size":39661},{"description":"EXHIBIT 8.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/tm2413457d4_ex8-1.htm","primary":false,"translateUrl":"","linkName":"tm2413457d4_ex8-1.htm","type":"EX-8.1","id":"NTFILE4y6oUWeTSsrzBk4z","market":"us","size":24155},{"description":"EXHIBIT 23.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/tm2413457d4_ex23-1.htm","primary":false,"translateUrl":"","linkName":"tm2413457d4_ex23-1.htm","type":"EX-23.1","id":"NTFILE45hB9PWikfUKXU2r","market":"us","size":2493},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/bc_ngstrains-4clr.jpg","primary":false,"translateUrl":"","linkName":"bc_ngstrains-4clr.jpg","type":"GRAPHIC","id":"NTFILEESZrQuK6L3HAYjU5","market":"us","size":61843},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/lg_evaxionaiimmunology-bwlr.jpg","primary":false,"translateUrl":"","linkName":"lg_evaxionaiimmunology-bwlr.jpg","type":"GRAPHIC","id":"NTFILE2Xo6zmxRHDRAMvyx","market":"us","size":10983},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/tb_screeningpembro-4clr.jpg","primary":false,"translateUrl":"","linkName":"tb_screeningpembro-4clr.jpg","type":"GRAPHIC","id":"NTFILEgJ3Z4K4W6a9Dwdb4","market":"us","size":31981},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/tb_stageofdev-4clr.jpg","primary":false,"translateUrl":"","linkName":"tb_stageofdev-4clr.jpg","type":"GRAPHIC","id":"NTFILE8k4oe6hMN2QD4dbT","market":"us","size":82669},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/tb_treatmentgroups-4clr.jpg","primary":false,"translateUrl":"","linkName":"tb_treatmentgroups-4clr.jpg","type":"GRAPHIC","id":"NTFILE5zqXu1ubCQPL3c9E","market":"us","size":43283},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/image_001.jpg","primary":false,"translateUrl":"","linkName":"image_001.jpg","type":"GRAPHIC","id":"NTFILEEAfp3nozsqUeWpMm","market":"us","size":7524},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/image_003.jpg","primary":false,"translateUrl":"","linkName":"image_003.jpg","type":"GRAPHIC","id":"NTFILEHfgATDtmEtmQEyb3","market":"us","size":1401},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924081492/image_002.jpg","primary":false,"translateUrl":"","linkName":"image_002.jpg","type":"GRAPHIC","id":"NTFILE5EMvic1KpiJ3zuG9","market":"us","size":2803}],"type_name":"Recruitment Registration","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"招股注册","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[Amend]Public Prospectus","pubTime":"2024-07-22 12:00","pubTimestamp":1721620800,"title_zh":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18104450","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924057512-EVAX","pdf_url":"","pub_time":1714968000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1 - Registration statement for certain foreign private issuers","symbol":"EVAX","title":"Form F-1 - Registration statement for certain foreign private issuers","titleType":"Public Prospectus","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924057512/0001104659-24-057512-index.htm","us_notice_code":"Form F-1","us_title_en":"Form F-1 - Registration statement for certain foreign private issuers","is_important":0,"hasEarnInfos":false,"gpt_zh_title":null,"gpt_en_title":null,"attachments":[{"description":"FORM F-1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924057512/tm2413457-1_f1.htm","primary":true,"translateUrl":"","linkName":"tm2413457-1_f1.htm","type":"F-1","id":"NTFILE4rWUqycDktFQxZ6t","market":"us","size":1044282},{"description":"EXHIBIT 23.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924057512/tm2413457d2_ex23-1.htm","primary":false,"translateUrl":"","linkName":"tm2413457d2_ex23-1.htm","type":"EX-23.1","id":"NTFILEHt8FWXTQQpm1DBLR","market":"us","size":2365},{"description":"EX-FILING FEES","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924057512/tm2413457d2_ex-filingfees.htm","primary":false,"translateUrl":"","linkName":"tm2413457d2_ex-filingfees.htm","type":"EX-FILING FEES","id":"NTFILEJ7FjwoexYDeEJLc7","market":"us","size":20307},{"description":"GRAPHIC","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924057512/lg_evaxionaiimmunology-bwlr.jpg","primary":false,"translateUrl":"","linkName":"lg_evaxionaiimmunology-bwlr.jpg","type":"GRAPHIC","id":"NTFILEnxGEBHaWTFccBfEM","market":"us","size":10983}],"type_name":"Recruitment Registration","type_name_en":"Recruitment Registration","titleTypeEn":"Public Prospectus","us_type":"招股注册","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"Public Prospectus","pubTime":"2024-05-06 12:00","pubTimestamp":1714968000,"title_zh":"Form F-1 - Registration statement for certain foreign private issuers","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"17756633","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924039004-EVAX","pdf_url":"","pub_time":1711425600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","symbol":"EVAX","title":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","titleType":"Annual Report","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/0001104659-24-039004-index.htm","us_notice_code":"Form 20-F","us_title_en":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":null,"gpt_en_title":null,"attachments":[{"description":"FORM 20-F","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f.htm","primary":true,"translateUrl":"","linkName":"evax-20231231x20f.htm","type":"20-F","id":"NTFILE8UQg6gkje8XpnEgq","market":"us","size":5890257},{"description":"EXHIBIT 12.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231xex12d1.htm","primary":false,"translateUrl":"","linkName":"evax-20231231xex12d1.htm","type":"EX-12.1","id":"NTFILE7djz569i81MmsFxf","market":"us","size":8021},{"description":"EXHIBIT 12.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231xex12d2.htm","primary":false,"translateUrl":"","linkName":"evax-20231231xex12d2.htm","type":"EX-12.2","id":"NTFILEDQYJZLZjPtUU8zXH","market":"us","size":8089},{"description":"EXHIBIT 13.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231xex13d1.htm","primary":false,"translateUrl":"","linkName":"evax-20231231xex13d1.htm","type":"EX-13.1","id":"NTFILE6x5qS7fdMXGdQWNk","market":"us","size":4559},{"description":"EXHIBIT 13.2","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231xex13d2.htm","primary":false,"translateUrl":"","linkName":"evax-20231231xex13d2.htm","type":"EX-13.2","id":"NTFILEAesHXGJusXY7AWh8","market":"us","size":5896},{"description":"EXHIBIT 15.1","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231xex15d1.htm","primary":false,"translateUrl":"","linkName":"evax-20231231xex15d1.htm","type":"EX-15.1","id":"NTFILE5hD5qYKu16enyMzM","market":"us","size":4168},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f005.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f005.jpg","type":"GRAPHIC","id":"NTFILEC8hR7VFVaRdYEAAf","market":"us","size":68727},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f006.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f006.jpg","type":"GRAPHIC","id":"NTFILE4SfT2VWTqsPMgrt2","market":"us","size":90328},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f007.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f007.jpg","type":"GRAPHIC","id":"NTFILEEuMAtbpkAi4JsJju","market":"us","size":57268},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f008.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f008.jpg","type":"GRAPHIC","id":"NTFILE7KNtEhEvubwLJ9Rb","market":"us","size":74551},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f009.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f009.jpg","type":"GRAPHIC","id":"NTFILE57976VL9JtGPtoQF","market":"us","size":66232},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f010.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f010.jpg","type":"GRAPHIC","id":"NTFILE7yvCPn95HNgFgg2A","market":"us","size":19671},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f011.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f011.jpg","type":"GRAPHIC","id":"NTFILE7vmQ8X9cqM8naKV2","market":"us","size":23408},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f012.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f012.jpg","type":"GRAPHIC","id":"NTFILEBxusQjUT8TkSJGBC","market":"us","size":24833},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f013.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f013.jpg","type":"GRAPHIC","id":"NTFILEGFx8qDwvgdEPAj6e","market":"us","size":22551},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f014.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f014.jpg","type":"GRAPHIC","id":"NTFILEdd18NmWcd7KUWsnf","market":"us","size":54866},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f015.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f015.jpg","type":"GRAPHIC","id":"NTFILEHT3nyPYywiLaQfHU","market":"us","size":41201},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f016.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f016.jpg","type":"GRAPHIC","id":"NTFILE6tqgzNpXjGgpCbAc","market":"us","size":62162},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f017.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f017.jpg","type":"GRAPHIC","id":"NTFILE6SSrK9ewSJm2Y6Rh","market":"us","size":34354},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f018.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f018.jpg","type":"GRAPHIC","id":"NTFILEGqHhFvKMYVYN6tNh","market":"us","size":36190},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f019.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f019.jpg","type":"GRAPHIC","id":"NTFILECHDmLUvt7wUGCCJP","market":"us","size":22053},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f020.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f020.jpg","type":"GRAPHIC","id":"NTFILE31bFbLG6kkMRLZ3N","market":"us","size":34608},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f021.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f021.jpg","type":"GRAPHIC","id":"NTFILE8PT5FhBGRqMMZaNx","market":"us","size":32954},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f022.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f022.jpg","type":"GRAPHIC","id":"NTFILEEsh1VnDw8RBKdWNJ","market":"us","size":51092},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f023.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f023.jpg","type":"GRAPHIC","id":"NTFILE4NmnwpgWSwT9UU8N","market":"us","size":17971},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f024.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f024.jpg","type":"GRAPHIC","id":"NTFILECxEV3zwGApKqgdqa","market":"us","size":47283},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f025.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f025.jpg","type":"GRAPHIC","id":"NTFILE58satjs6yRtTnYpZ","market":"us","size":27996},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f026.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f026.jpg","type":"GRAPHIC","id":"NTFILE8PUsiP3i9fCAoCku","market":"us","size":20875},{"description":"GRAPHIC","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f027.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f027.jpg","type":"GRAPHIC","id":"NTFILEDmxTucy899wDkR5b","market":"us","size":50567},{"description":"GRAPHIC","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f028.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f028.jpg","type":"GRAPHIC","id":"NTFILEAo1KAyMf7wY3CMSi","market":"us","size":55343},{"description":"GRAPHIC","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f029.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f029.jpg","type":"GRAPHIC","id":"NTFILE3fJysUSk2xuAz5q2","market":"us","size":47452},{"description":"GRAPHIC","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f030.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f030.jpg","type":"GRAPHIC","id":"NTFILEGdTAJxsGmjuutKhv","market":"us","size":28368},{"description":"GRAPHIC","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f031.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f031.jpg","type":"GRAPHIC","id":"NTFILEDv2PsJm4teAXz8Py","market":"us","size":17994},{"description":"GRAPHIC","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f032.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f032.jpg","type":"GRAPHIC","id":"NTFILEDRHouJWWj25C96mE","market":"us","size":47184},{"description":"GRAPHIC","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f033.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f033.jpg","type":"GRAPHIC","id":"NTFILEpa32znKEkpKSsBNd","market":"us","size":37801},{"description":"GRAPHIC","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f034.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f034.jpg","type":"GRAPHIC","id":"NTFILEA52x3ke42aJQ4KCn","market":"us","size":59408},{"description":"GRAPHIC","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f035.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f035.jpg","type":"GRAPHIC","id":"NTFILE8BhQu4rcJbPtSBa5","market":"us","size":152335},{"description":"GRAPHIC","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f036.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f036.jpg","type":"GRAPHIC","id":"NTFILE5F7VzgnBWFGXgu7q","market":"us","size":47812},{"description":"GRAPHIC","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f037.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f037.jpg","type":"GRAPHIC","id":"NTFILE6rxCBqZy8gM2xgv9","market":"us","size":28163},{"description":"GRAPHIC","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f038.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f038.jpg","type":"GRAPHIC","id":"NTFILEDdhWvgunn7M1yn9T","market":"us","size":16149},{"description":"GRAPHIC","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f039.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f039.jpg","type":"GRAPHIC","id":"NTFILE9PxpsuKUS2zTjnkC","market":"us","size":20604},{"description":"GRAPHIC","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f040.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f040.jpg","type":"GRAPHIC","id":"NTFILEBTnn2YyiHtH6NwSr","market":"us","size":18660},{"description":"GRAPHIC","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f041.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f041.jpg","type":"GRAPHIC","id":"NTFILE9DgH34znnUUh34zq","market":"us","size":21734},{"description":"GRAPHIC","seq":49,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f042.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f042.jpg","type":"GRAPHIC","id":"NTFILE8FiC5MTP83eAn8K5","market":"us","size":21858},{"description":"GRAPHIC","seq":50,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f043.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f043.jpg","type":"GRAPHIC","id":"NTFILE78LBX1T7kERDzfNg","market":"us","size":52133},{"description":"GRAPHIC","seq":51,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f044.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f044.jpg","type":"GRAPHIC","id":"NTFILEGwmVY4wXLyDBTbEn","market":"us","size":30056},{"description":"GRAPHIC","seq":52,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f045.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f045.jpg","type":"GRAPHIC","id":"NTFILE8N3XeE62PhCoQ7AL","market":"us","size":18517},{"description":"GRAPHIC","seq":53,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f046.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f046.jpg","type":"GRAPHIC","id":"NTFILE8nL3ZxmcafirLViJ","market":"us","size":25282},{"description":"GRAPHIC","seq":54,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f047.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f047.jpg","type":"GRAPHIC","id":"NTFILEBoEfHSnUokSUojfv","market":"us","size":54754},{"description":"GRAPHIC","seq":55,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f048.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f048.jpg","type":"GRAPHIC","id":"NTFILEa8itUdp1Z9Z1p6TY","market":"us","size":47704},{"description":"GRAPHIC","seq":56,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f049.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f049.jpg","type":"GRAPHIC","id":"NTFILE9KoGbz5yQ7fd8Nvr","market":"us","size":30364},{"description":"GRAPHIC","seq":57,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924039004/evax-20231231x20f050.jpg","primary":false,"translateUrl":"","linkName":"evax-20231231x20f050.jpg","type":"GRAPHIC","id":"NTFILEDR9BywNaEXHcBfQ1","market":"us","size":11274}],"type_name":"Financial Report","type_name_en":"Financial Report","titleTypeEn":"Annual Report","us_type":"财务报告","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"Annual Report","pubTime":"2024-03-26 12:00","pubTimestamp":1711425600,"title_zh":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"17540264","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924008874-EVAX","pdf_url":"","pub_time":1706677200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","symbol":"EVAX","title":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","titleType":"[Amend]Public Prospectus","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/0001104659-24-008874-index.htm","us_notice_code":"Form F-1/A","us_title_en":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":null,"gpt_en_title":null,"attachments":[{"description":"F-1/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/tm2334005-6_f1a.htm","primary":true,"translateUrl":"","linkName":"tm2334005-6_f1a.htm","type":"F-1/A","id":"NTFILE4GPFg5NUBfqCPz6W","market":"us","size":5743202},{"description":"EXHIBIT1.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/tm2334005d8_ex1-1.htm","primary":false,"translateUrl":"","linkName":"tm2334005d8_ex1-1.htm","type":"EX-1.1","id":"NTFILE7ZzrYjLS7zgHdeip","market":"us","size":87377},{"description":"GRAPHIC","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig13pioneer-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig13pioneer-4c.jpg","type":"GRAPHIC","id":"NTFILEHjVj2TfarW2dFfeo","market":"us","size":30201},{"description":"GRAPHIC","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig16stage-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig16stage-4c.jpg","type":"GRAPHIC","id":"NTFILEBs5eXw5YL5ygKCRC","market":"us","size":30594},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig19lesions-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig19lesions-4c.jpg","type":"GRAPHIC","id":"NTFILEpoZWNxK3yt7EkyFE","market":"us","size":41911},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig43kidneys-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig43kidneys-4c.jpg","type":"GRAPHIC","id":"NTFILE3ixFFVjBFaSKbfHQ","market":"us","size":25167},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig47immunization-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig47immunization-4c.jpg","type":"GRAPHIC","id":"NTFILE38tbLADwcwn6sNd3","market":"us","size":26783},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig48splenocytes-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig48splenocytes-4c.jpg","type":"GRAPHIC","id":"NTFILEER19ijVZqNDuA4e2","market":"us","size":35423},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig49akilling-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig49akilling-4c.jpg","type":"GRAPHIC","id":"NTFILEVYhCyXAHHd3622WZ","market":"us","size":76748},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig49killing-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig49killing-4c.jpg","type":"GRAPHIC","id":"NTFILE893SzYBeq8ehxTRf","market":"us","size":38699},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig51tcellresponse-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig51tcellresponse-4c.jpg","type":"GRAPHIC","id":"NTFILEDPYEnRyDLBEgrqcY","market":"us","size":43939},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/bc_fig52antibody-4c.jpg","primary":false,"translateUrl":"","linkName":"bc_fig52antibody-4c.jpg","type":"GRAPHIC","id":"NTFILE9tmGTyKDr6y8J2qM","market":"us","size":22079},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig03aiimmunolonew-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_fig03aiimmunolonew-4clr.jpg","type":"GRAPHIC","id":"NTFILEXTHpeEiNV9RTkLbk","market":"us","size":99521},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig05stagedevelop-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig05stagedevelop-4c.jpg","type":"GRAPHIC","id":"NTFILEEyGzA66td7VvnfWG","market":"us","size":45718},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig06ourstarat-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig06ourstarat-4c.jpg","type":"GRAPHIC","id":"NTFILE7qSiyr6hJ95ebvMB","market":"us","size":112297},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig12cancer-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig12cancer-4c.jpg","type":"GRAPHIC","id":"NTFILEGvyMWcG3R96qWAV8","market":"us","size":43857},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig15pioneer-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig15pioneer-4c.jpg","type":"GRAPHIC","id":"NTFILEC3potWDdeck5v1tQ","market":"us","size":42345},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig17vaccine-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_fig17vaccine-4clr.jpg","type":"GRAPHIC","id":"NTFILEGp5tpvkYcjDDvUon","market":"us","size":82873},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig24pembrolizumab-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig24pembrolizumab-4c.jpg","type":"GRAPHIC","id":"NTFILE9eVqjCsL5b9899qi","market":"us","size":21785},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig36discovery-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig36discovery-4c.jpg","type":"GRAPHIC","id":"NTFILE8cgwCAptcEBVaM4E","market":"us","size":127689},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig38eden-4clr.jpg","primary":false,"translateUrl":"","linkName":"fc_fig38eden-4clr.jpg","type":"GRAPHIC","id":"NTFILE2KNvnubQEtm9xyMQ","market":"us","size":115130},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig39vaccine-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig39vaccine-4c.jpg","type":"GRAPHIC","id":"NTFILE3jzeLaJoTJMnhA2B","market":"us","size":56940},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig44glase-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig44glase-4c.jpg","type":"GRAPHIC","id":"NTFILECgsFutgB8QwrwWdc","market":"us","size":119623},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/fc_fig50panproteome-4c.jpg","primary":false,"translateUrl":"","linkName":"fc_fig50panproteome-4c.jpg","type":"GRAPHIC","id":"NTFILE9RuRcsFVHkN9UEyb","market":"us","size":82816},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig14tumorvolum-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig14tumorvolum-4c.jpg","type":"GRAPHIC","id":"NTFILE48zdx77ejAWujxyX","market":"us","size":78226},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig20prepost-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_fig20prepost-bw.jpg","type":"GRAPHIC","id":"NTFILEGWedHZC3znSEvsV5","market":"us","size":55776},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig21prepostfollow-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_fig21prepostfollow-bw.jpg","type":"GRAPHIC","id":"NTFILECzWyf1ys7WTyqyUG","market":"us","size":44542},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig22mannwhitney-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_fig22mannwhitney-bw.jpg","type":"GRAPHIC","id":"NTFILE9x5jT5pZchW3Ps64","market":"us","size":42349},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig23neoantigen-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig23neoantigen-4c.jpg","type":"GRAPHIC","id":"NTFILE3JGjDKMrmypHp52S","market":"us","size":70709},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig27tumor-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig27tumor-4c.jpg","type":"GRAPHIC","id":"NTFILE6MXQTnbxFVPkW4rQ","market":"us","size":38500},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig28isotype-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig28isotype-4c.jpg","type":"GRAPHIC","id":"NTFILE62j2zxVgRUFZRsPk","market":"us","size":52750},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig29control-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig29control-4c.jpg","type":"GRAPHIC","id":"NTFILEBfztXcoNMKsFbA8W","market":"us","size":75360},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig30inoculation-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig30inoculation-4c.jpg","type":"GRAPHIC","id":"NTFILECa13HKAR6evYKMMj","market":"us","size":69578},{"description":"GRAPHIC","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig31backbone-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig31backbone-4c.jpg","type":"GRAPHIC","id":"NTFILE8GWLqX39hgQU1M8U","market":"us","size":49275},{"description":"GRAPHIC","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig33clinical-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_fig33clinical-bw.jpg","type":"GRAPHIC","id":"NTFILE9BJP1e3EU2HCqY81","market":"us","size":96970},{"description":"GRAPHIC","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig34liuhugovan-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig34liuhugovan-4c.jpg","type":"GRAPHIC","id":"NTFILE3Bo5gyqKkrQLTEbd","market":"us","size":53554},{"description":"GRAPHIC","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig37neisseria-bw.jpg","primary":false,"translateUrl":"","linkName":"lc_fig37neisseria-bw.jpg","type":"GRAPHIC","id":"NTFILE62i6sEy3hRP24swH","market":"us","size":142520},{"description":"GRAPHIC","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig40evxb1-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig40evxb1-4c.jpg","type":"GRAPHIC","id":"NTFILEHF5nwSD8kBddawzY","market":"us","size":23812},{"description":"GRAPHIC","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig41abcess-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig41abcess-4c.jpg","type":"GRAPHIC","id":"NTFILE3HTkyPbF33LRTqtq","market":"us","size":37370},{"description":"GRAPHIC","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig42halfmax-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig42halfmax-4c.jpg","type":"GRAPHIC","id":"NTFILEASoiNZttVLSUtv5a","market":"us","size":21351},{"description":"GRAPHIC","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig45evxb2-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig45evxb2-4c.jpg","type":"GRAPHIC","id":"NTFILEGvzh1PqgMzkbmFV8","market":"us","size":98294},{"description":"GRAPHIC","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lc_fig46auclog-4c.jpg","primary":false,"translateUrl":"","linkName":"lc_fig46auclog-4c.jpg","type":"GRAPHIC","id":"NTFILEBMkQjRpHmBk3XaED","market":"us","size":63204},{"description":"GRAPHIC","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/lg_evaxionaiimmunology-bwlr.jpg","primary":false,"translateUrl":"","linkName":"lg_evaxionaiimmunology-bwlr.jpg","type":"GRAPHIC","id":"NTFILE8DqjdwxYKVrMaTzZ","market":"us","size":10969},{"description":"GRAPHIC","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/pc_fig04aiimmunolo-4c.jpg","primary":false,"translateUrl":"","linkName":"pc_fig04aiimmunolo-4c.jpg","type":"GRAPHIC","id":"NTFILE31WUjvrY2vVCnAjc","market":"us","size":57315},{"description":"GRAPHIC","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/ph_fig25week-4c.jpg","primary":false,"translateUrl":"","linkName":"ph_fig25week-4c.jpg","type":"GRAPHIC","id":"NTFILEBX3ZtwWxEEPzxzVa","market":"us","size":117538},{"description":"GRAPHIC","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/ph_fig26evx2evx3-4clr.jpg","primary":false,"translateUrl":"","linkName":"ph_fig26evx2evx3-4clr.jpg","type":"GRAPHIC","id":"NTFILE2jP9PeU2erpPB14Z","market":"us","size":78952},{"description":"GRAPHIC","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/ph_fig35bacterial-4c.jpg","primary":false,"translateUrl":"","linkName":"ph_fig35bacterial-4c.jpg","type":"GRAPHIC","id":"NTFILE57K1mEnf58VQRUDj","market":"us","size":56165},{"description":"GRAPHIC","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/tb_fig02milestones-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_fig02milestones-4c.jpg","type":"GRAPHIC","id":"NTFILEGBtuBxXQntkH3vkZ","market":"us","size":67060},{"description":"GRAPHIC","seq":49,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/tb_fig18tumor-4c.jpg","primary":false,"translateUrl":"","linkName":"tb_fig18tumor-4c.jpg","type":"GRAPHIC","id":"NTFILEEcLW7Qqf6cav4pVe","market":"us","size":76653},{"description":"GRAPHIC","seq":50,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/tb_fig20trae-4clr.jpg","primary":false,"translateUrl":"","linkName":"tb_fig20trae-4clr.jpg","type":"GRAPHIC","id":"NTFILE32JGTvn1Fb8gSE8e","market":"us","size":21615},{"description":"GRAPHIC","seq":51,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/tb_fig32inoculatnew-4clr.jpg","primary":false,"translateUrl":"","linkName":"tb_fig32inoculatnew-4clr.jpg","type":"GRAPHIC","id":"NTFILEGqHQoQmtMNFF6qde","market":"us","size":45681},{"description":"GRAPHIC","seq":52,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/tm2334005d7_ex1-1img001.jpg","primary":false,"translateUrl":"","linkName":"tm2334005d7_ex1-1img001.jpg","type":"GRAPHIC","id":"NTFILE96e4aDcUZKaoAGdy","market":"us","size":7760},{"description":"GRAPHIC","seq":53,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1828253/000110465924008874/tm2334005d8_ex1-1aimg01.jpg","primary":false,"translateUrl":"","linkName":"tm2334005d8_ex1-1aimg01.jpg","type":"GRAPHIC","id":"NTFILEAoHvk4FrGmtokNEp","market":"us","size":8318}],"type_name":"Recruitment Registration","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"招股注册","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[Amend]Public Prospectus","pubTime":"2024-01-31 13:00","pubTimestamp":1706677200,"title_zh":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.evaxionbiotech.com","stockEarnings":[{"period":"1week","weight":-0.081},{"period":"1month","weight":-0.3095},{"period":"3month","weight":-0.5185},{"period":"6month","weight":-0.9022},{"period":"1year","weight":-0.9394},{"period":"ytd","weight":-0.6913}],"compareEarnings":[{"period":"1week","weight":-0.0468},{"period":"1month","weight":-0.0888},{"period":"3month","weight":-0.1479},{"period":"6month","weight":-0.1109},{"period":"1year","weight":0.0378},{"period":"ytd","weight":-0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.307156},{"month":2,"riseRate":0,"avgChangeRate":-0.092268},{"month":3,"riseRate":0,"avgChangeRate":-0.116351},{"month":4,"riseRate":0.6,"avgChangeRate":0.051228},{"month":5,"riseRate":0.25,"avgChangeRate":-0.067063},{"month":6,"riseRate":0.25,"avgChangeRate":-0.055002},{"month":7,"riseRate":0.25,"avgChangeRate":0.052601},{"month":8,"riseRate":0.5,"avgChangeRate":-0.067943},{"month":9,"riseRate":1,"avgChangeRate":0.154645},{"month":10,"riseRate":0.25,"avgChangeRate":-0.004732},{"month":11,"riseRate":0,"avgChangeRate":-0.303517},{"month":12,"riseRate":0,"avgChangeRate":-0.217452}],"exchange":"NASDAQ","name":"Evaxion Biotech A/S","nameEN":"Evaxion Biotech A/S"},"aProfile":null}}}

Evaxion Biotech A/S(EVAX)

Company Profile